

    <!DOCTYPE html>
<html class="">

        
<head>
    <title>Malaria vaccines targeting the pre-erythrocytic... | F1000Research</title>
    <meta charset="utf-8">
    <!--<meta http-equiv="Content-Type" content="text/html; charset=utf-8"/>-->
    <!--<meta lang="$locale">-->
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta name="google-site-verification" content="9-QVycOO2_ob3Z9QzRmXv2CF08A9oyYXqWyTiVdKPlU" />
    <!-- This is commented out to fix display problems on mobile devices.
    We may use it again once we implement a responsive design that supports native device resolutions.
    <meta name="viewport" content="width=device-width"> -->

    <meta name="viewport" content="width=device-width, initial-scale=1, maximum-scale=1">



    <link rel="alternate" title="Recent articles published in F1000Research" href="/rss" type="application/rss+xml">
            <link rel="alternate" type="application/pdf" title="PDF" href="https://f1000research.com/articles/9-680/pdf"/>
        <link rel="canonical" href="https://f1000research.com/articles/9-680" />
    
            <meta name="description" content="Read the original article in full on F1000Research: Malaria vaccines targeting the pre-erythrocytic stage: a scoping review" />
    
            <meta name="og:title" content="F1000Research Article: Malaria vaccines targeting the pre-erythrocytic stage: a scoping review.">
            <meta name="og:description" content="Read the latest article version by Teresa Ogeto, Ferdinand Ndubi, Mary Murithi, Richard Kagia, Esbon Wambugu, Titus Suge, Carolyne Chepkirui, Josephat Tonui, Fiona Maiyo, Lydia Momanyi, Michael Walekhwa, at F1000Research.">
            <meta name="og:image" content="/img/sharing/og_research.png">
            <meta name="version-id" content="26833">
            <meta name="article-id" content="24320">
            <meta name="dc.title" content="Malaria vaccines targeting the pre-erythrocytic stage: a scoping review">
            <meta name="dc.description" content="Malaria is a deadly infectious parasitic disease that causes devastating morbidity and mortality globally. Despite being a public health concern, an effective vaccine for prevention of the disease remains elusive. Global efforts are exploring possible ways of developing and improving vaccines to counteract the complex nature in which Plasmodium falciparum evades the immune system. A number of vaccines have been developed in the past targeting the various parasitic life cycle stages. Transmission blocker vaccines, such as PpPf S25, target the parasite stages in the mosquito vector. However, these herd vaccines only protect the immunized population. Vaccines targeting blood-stage forms, such as the AMA-1 and MSP-1 vaccines, are challenged by the complex metabolic pathways of erythrocytes and merozoites. Vaccines targeting the pre-erythrocytic sporozoite stage remain the most promising approach thus far. Here, we systematically review the literature on pre-erythrocytic stage vaccines and on-going work in the field. Furthermore, we highlight gaps in current knowledge and point to potential areas of future work. Articles on pre-erythrocytic malaria vaccines were obtained from Google scholar, PubMed and Cochrane starting from the year 2010. Ten papers were reviewed. A number of vaccines were reviewed highlighting; the vaccine type, clinical phase of trial, population demographics, vaccine immunogenicity, efficacy and safety. The RTS,S vaccine is reportedly the most advanced, having been rolled out for phase III clinical trials in a number of malaria-endemic African countries. The pre-erythrocytic vaccines discussed have made milestones in clinical trials. Some of the challenges elicited may be addressed via screening for novel antigens, exploring suitable vaccine administration vehicles,&amp;shy; as well as using a combined multi-stage vaccine approach.">
            <meta name="dc.subject" content="Malaria, Pre-erythrocytic, Plasmodium falciparum, Vaccines, Sporozoites, efficacy">
            <meta name="dc.creator" content="Ogeto, Teresa">
            <meta name="dc.creator" content="Ndubi, Ferdinand">
            <meta name="dc.creator" content="Murithi, Mary">
            <meta name="dc.creator" content="Kagia, Richard">
            <meta name="dc.creator" content="Wambugu, Esbon">
            <meta name="dc.creator" content="Suge, Titus">
            <meta name="dc.creator" content="Chepkirui, Carolyne">
            <meta name="dc.creator" content="Tonui, Josephat">
            <meta name="dc.creator" content="Maiyo, Fiona">
            <meta name="dc.creator" content="Momanyi, Lydia">
            <meta name="dc.creator" content="Walekhwa, Michael">
            <meta name="dc.date" content="2020/07/07">
            <meta name="dc.identifier" content="doi:10.12688/f1000research.24320.1">
            <meta name="dc.source" content="F1000Research 2020 9:680">
            <meta name="dc.format" content="text/html">
            <meta name="dc.language" content="en">
            <meta name="dc.publisher" content="F1000 Research Limited">
            <meta name="dc.rights" content="https://creativecommons.org/licenses/by/3.0/igo/">
            <meta name="dc.type" content="text">
            <meta name="prism.keyword" content="Malaria">
            <meta name="prism.keyword" content="Pre-erythrocytic">
            <meta name="prism.keyword" content="Plasmodium falciparum">
            <meta name="prism.keyword" content="Vaccines">
            <meta name="prism.keyword" content="Sporozoites">
            <meta name="prism.keyword" content="efficacy">
            <meta name="prism.publication.Name" content="F1000Research">
            <meta name="prism.publicationDate" content="2020/07/07">
            <meta name="prism.volume" content="9">
            <meta name="prism.number" content="680">
            <meta name="prism.versionIdentifier" content="1">
            <meta name="prism.doi" content="10.12688/f1000research.24320.1">
            <meta name="prism.url" content="https://f1000research.com/articles/9-680">
            <meta name="citation_title" content="Malaria vaccines targeting the pre-erythrocytic stage: a scoping review">
            <meta name="citation_abstract" content="Malaria is a deadly infectious parasitic disease that causes devastating morbidity and mortality globally. Despite being a public health concern, an effective vaccine for prevention of the disease remains elusive. Global efforts are exploring possible ways of developing and improving vaccines to counteract the complex nature in which Plasmodium falciparum evades the immune system. A number of vaccines have been developed in the past targeting the various parasitic life cycle stages. Transmission blocker vaccines, such as PpPf S25, target the parasite stages in the mosquito vector. However, these herd vaccines only protect the immunized population. Vaccines targeting blood-stage forms, such as the AMA-1 and MSP-1 vaccines, are challenged by the complex metabolic pathways of erythrocytes and merozoites. Vaccines targeting the pre-erythrocytic sporozoite stage remain the most promising approach thus far. Here, we systematically review the literature on pre-erythrocytic stage vaccines and on-going work in the field. Furthermore, we highlight gaps in current knowledge and point to potential areas of future work. Articles on pre-erythrocytic malaria vaccines were obtained from Google scholar, PubMed and Cochrane starting from the year 2010. Ten papers were reviewed. A number of vaccines were reviewed highlighting; the vaccine type, clinical phase of trial, population demographics, vaccine immunogenicity, efficacy and safety. The RTS,S vaccine is reportedly the most advanced, having been rolled out for phase III clinical trials in a number of malaria-endemic African countries. The pre-erythrocytic vaccines discussed have made milestones in clinical trials. Some of the challenges elicited may be addressed via screening for novel antigens, exploring suitable vaccine administration vehicles,&amp;shy; as well as using a combined multi-stage vaccine approach.">
            <meta name="citation_description" content="Malaria is a deadly infectious parasitic disease that causes devastating morbidity and mortality globally. Despite being a public health concern, an effective vaccine for prevention of the disease remains elusive. Global efforts are exploring possible ways of developing and improving vaccines to counteract the complex nature in which Plasmodium falciparum evades the immune system. A number of vaccines have been developed in the past targeting the various parasitic life cycle stages. Transmission blocker vaccines, such as PpPf S25, target the parasite stages in the mosquito vector. However, these herd vaccines only protect the immunized population. Vaccines targeting blood-stage forms, such as the AMA-1 and MSP-1 vaccines, are challenged by the complex metabolic pathways of erythrocytes and merozoites. Vaccines targeting the pre-erythrocytic sporozoite stage remain the most promising approach thus far. Here, we systematically review the literature on pre-erythrocytic stage vaccines and on-going work in the field. Furthermore, we highlight gaps in current knowledge and point to potential areas of future work. Articles on pre-erythrocytic malaria vaccines were obtained from Google scholar, PubMed and Cochrane starting from the year 2010. Ten papers were reviewed. A number of vaccines were reviewed highlighting; the vaccine type, clinical phase of trial, population demographics, vaccine immunogenicity, efficacy and safety. The RTS,S vaccine is reportedly the most advanced, having been rolled out for phase III clinical trials in a number of malaria-endemic African countries. The pre-erythrocytic vaccines discussed have made milestones in clinical trials. Some of the challenges elicited may be addressed via screening for novel antigens, exploring suitable vaccine administration vehicles,&amp;shy; as well as using a combined multi-stage vaccine approach.">
            <meta name="citation_keywords" content="Malaria, Pre-erythrocytic, Plasmodium falciparum, Vaccines, Sporozoites, efficacy">
            <meta name="citation_journal_title" content="F1000Research">
            <meta name="citation_author" content="Teresa Ogeto">
            <meta name="citation_author_institution" content="Department of Biomedical Sciences, Kabarak University, Nakuru, Kenya, 20157, Kenya">
            <meta name="citation_author" content="Ferdinand Ndubi">
            <meta name="citation_author_institution" content="Department of Pharmaceutical Chemistry &amp; Pharmaceutics, Kabarak University, Nakuru, Kenya, 20157, Kenya">
            <meta name="citation_author" content="Mary Murithi">
            <meta name="citation_author_institution" content="Department of Pre-Clinical, Kabarak University, Nakuru, Kenya, 20157, Kenya">
            <meta name="citation_author" content="Richard Kagia">
            <meta name="citation_author_institution" content="Pharmacology &amp; Pharmacognosy, Kabarak University, Nakuru, Kenya, 20157, Kenya">
            <meta name="citation_author" content="Esbon Wambugu">
            <meta name="citation_author_institution" content="Pharmacology &amp; Pharmacognosy, Kabarak University, Nakuru, Kenya, 20157, Kenya">
            <meta name="citation_author" content="Titus Suge">
            <meta name="citation_author_institution" content="Pharmacology &amp; Pharmacognosy, Kabarak University, Nakuru, Kenya, 20157, Kenya">
            <meta name="citation_author" content="Carolyne Chepkirui">
            <meta name="citation_author_institution" content="Department of Physical &amp; Biological Sciences, Kabarak University, Nakuru, Kenya, 20157, Kenya">
            <meta name="citation_author" content="Josephat Tonui">
            <meta name="citation_author_institution" content="Department of Biomedical Sciences, Kabarak University, Nakuru, Kenya, 20157, Kenya">
            <meta name="citation_author" content="Fiona Maiyo">
            <meta name="citation_author_institution" content="Department of Biomedical Sciences, Kabarak University, Nakuru, Kenya, 20157, Kenya">
            <meta name="citation_author" content="Lydia Momanyi">
            <meta name="citation_author_institution" content="Department of Pharmacy, Nakuru Level V Hospital, Nakuru, Kenya, 20157, Kenya">
            <meta name="citation_author" content="Michael Walekhwa">
            <meta name="citation_author_institution" content="Department of Biomedical Sciences, Kabarak University, Nakuru, Kenya, 20157, Kenya">
            <meta name="citation_publication_date" content="2020/07/07">
            <meta name="citation_volume" content="9">
            <meta name="citation_publication_number" content="680">
            <meta name="citation_version_number" content="1">
            <meta name="citation_doi" content="10.12688/f1000research.24320.1">
            <meta name="citation_firstpage" content="680">
            <meta name="citation_pdf_url" content="https://f1000research.com/articles/9-680/v1/pdf">
    

    
    <link href="/img/favicon-research.ico" rel="shortcut icon" type="image/ico">
    <link href="/img/favicon-research.ico" rel="icon" type="image/ico">

        <link rel="stylesheet" href="/1597255280893/css/mdl/material-design-lite.css" type="text/css" media="all" />
    <link href="https://fonts.googleapis.com/icon?family=Material+Icons" rel="stylesheet">
    <link href="https://fonts.googleapis.com/css?family=Roboto:100,100i,300,300i,400,400i,500,500i,700,700i,900,900i" rel="stylesheet">
    <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/MaterialDesign-Webfont/2.2.43/css/materialdesignicons.min.css" />

        
            
    <link rel="stylesheet" href="/1597255280893/css/F1000Research.css" type="text/css" media="all" />
    <link rel="stylesheet" href="/css/F1000ResearchFontIcons/F1000ResearchFontIcons.css" type="text/css" media="all" />
    <link rel="stylesheet" href="/css/F1000ResearchFontIcons/animation.css" type="text/css" media="all" />

        <!--[if IE 7]><link rel="stylesheet" href="/css/F1000ResearchFontIcons/F1000ResearchFontIcons-ie7.css" media="all" /><![endif]-->

                    <script>dataLayer = [];</script>
        <!-- Google Tag Manager -->
        <script>(function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start':
        new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0],
        j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src=
        'https://www.googletagmanager.com/gtm.js?id='+i+dl;f.parentNode.insertBefore(j,f);
        })(window,document,'script','dataLayer','GTM-54Z2SBK');</script>
        <!-- End Google Tag Manager -->
    
    <script src="https://ajax.googleapis.com/ajax/libs/jquery/1.8.1/jquery.min.js"></script>
    <script>window.jQuery || document.write('<script src="/js/vendor/jquery-1.8.1.min.js"><\/script>')</script>
    <script src="/1597255280893/js/vendor/modernizr-2.6.1-respond-1.1.0.min.js"></script>
    <script src="/1597255280893/js/shared_scripts/sticky.js"></script>
    <script src="/1597255280893/js/shared_scripts/helpers.js"></script>
    <script src="/1597255280893/js/shared_scripts/menu.js"></script>
    <script src="/1597255280893/js/shared_scripts/navbar.js"></script>
    <script src="/1597255280893/js/shared_scripts/platforms.js"></script>
    <script src="/1597255280893/js/shared_scripts/object-polyfills.js"></script>
            <script src="/1597255280893/js/vendor/lodash.min.js"></script>
        <script>CKEDITOR_BASEPATH='https://f1000research.com/js/ckeditor/'</script>
    <script src="https://f1000researchdata.s3-eu-west-1.amazonaws.com/js/plugins.js"></script>
    <script src="/1597255280893/js/shared_scripts/helpers.js"></script>
    <script src="/1597255280893/js/app/research.js"></script>
    <script>window.reactTheme = 'research';</script>
    <script src="/1597255280893/js/public/bundle.js"></script>

    <script src="/1597255280893/js/app/research.ui.js"></script>
    <script src="/1597255280893/js/app/login.js"></script>
    <script src="/1597255280893/js/app/main.js"></script>
    <script src="/1597255280893/js/app/js-date-format.min.js"></script>
    <script src="/1597255280893/js/app/search.js"></script>
    <script src="/1597255280893/js/app/cookies_warning.js"></script>
    <script src="/1597255280893/js/mdl/mdl.min.js"></script>

    <script src="https://cdnjs.cloudflare.com/ajax/libs/mathjax/2.7.1/MathJax.js?config=TeX-AMS-MML_HTMLorMML"></script>
                <script src="https://f1000researchdata.s3-eu-west-1.amazonaws.com/js/ckeditor.js"></script>
            <script src="/js/ckeditor/adapters/jquery.js"></script>
                <script src="/js/article/article_scrolling_module.js"></script>
            <script src="/js/article/article_stats.js"></script>
            <script src="/js/article/article.js"></script>
            <script src="/js/shared_scripts/referee_timeline_pagination.js"></script>
            <script src="/js/app/text_editor_controller.js"></script>
            <script src="//s7.addthis.com/js/250/addthis_widget.js#pubid=ra-503e5e99593dc42c"></script>
            <script src="/js/article/article_metrics.js"></script>
        
                                                                            <script>
            if (window.location.hash == '#_=_'){
                window.location = window.location.href.split('#')[0]
            }
        </script>

                    
        
    <!-- pixelId: 1641728616063202 :: assetPixelId: 6034867600215 :: funderPixelId:  -->

            <!-- Facebook pixel code (merged with EP GTM code) -->
        <script>
            !function(f,b,e,v,n,t,s){if(f.fbq)return;n=f.fbq=function()

            {n.callMethod? n.callMethod.apply(n,arguments):n.queue.push(arguments)}
            ;if(!f._fbq)f._fbq=n;
            n.push=n;n.loaded=!0;n.version='2.0';n.queue=[];t=b.createElement(e);t.async=!0;
            t.src=v;s=b.getElementsByTagName(e)[0];s.parentNode.insertBefore(t,s)}(window,
            document,'script','https://connect.facebook.net/en_US/fbevents.js');

            fbq('init', '1641728616063202');

            
            fbq('track', "PixelInitialized", {});
        </script>

        <noscript><img height="1" width="1" style="display:none"
            src="https://www.facebook.com/tr?id=1641728616063202&noscript=1&amp;ev=PixelInitialized"
        /></noscript>
        <!-- End Facebook Pixel Code -->
    
                <script>
            (function(h,o,t,j,a,r){
                h.hj=h.hj||function(){(h.hj.q=h.hj.q||[]).push(arguments)};
                h._hjSettings={hjid:917825,hjsv:6};
                a=o.getElementsByTagName('head')[0];
                r=o.createElement('script');r.async=1;
                r.src=t+h._hjSettings.hjid+j+h._hjSettings.hjsv;
                a.appendChild(r);
            })(window,document,'https://static.hotjar.com/c/hotjar-','.js?sv=');
        </script>
    
</head>
<body  class="o-page-container no-js p-article o-layout-reset   ">

    
                            <!-- Google Tag Manager (noscript) -->
        <noscript><iframe src="https://www.googletagmanager.com/ns.html?id=GTM-54Z2SBK"
        height="0" width="0" style="display:none;visibility:hidden"></iframe></noscript>
        <!-- End Google Tag Manager (noscript) -->
    
        
    <div class="o-page">

        <div id="notify-container"></div>
        <div id="pageWarning"></div>
        <div id="pageMessage"></div>
        <div id="pageFooterMessage"></div>

                                <div id="f1r-ga-data" data-name="f1r-ga-data" class="f1r-ga-data"
                data-user-registered="false"
                data-user-module=""
                data-current-path=""
                data-location=""
                data-website="F1000Research"
                data-websiteDisplayName="F1000Research">
            </div>
        
                
        
        <div class="header-wrapper   js-navbar-space ">
                            


    










        
                            
    
            



<nav class="c-navbar js-navbar js-mini-nav js-sticky c-navbar--js-sticky c-navbar--userSite c-navbar__platform-bgcolor  c-navbar--bg-f1000research ">

    <div class="c-navbar__content">

                                <div class="c-navbar__extras">
            <div class="o-wrapper">
                <div class="o-actions o-actions--middle c-navbar__extras-row">
                    <div class="o-actions__primary">
                        
                                            </div>
                                    </div>
            </div>
        </div>

        <div class="o-wrapper t-inverted js-sticky-start">

            <div class="c-navbar__branding-row">
                <div class="c-navbar__row">


                                        
                    <div class="c-navbar__primary u-mr--2">

                                                                                                                                                                                                    <a href="/" class="c-navbar__branding u-ib u-middle"   data-test-id="nav_branding"  >
                                <img class="u-ib u-middle" src="/img/research/F1000Research_white_solid.svg" alt="F1000Research">
                            </a>
                                            </div>

                    <div class="c-navbar__secondary c-navbar__row">


                                                
                                                    <form action="/search" class="-navbar__secondary u-mr--2 c-search-form js-search-form u-hide u-show@navbar">
                                <label for="searchInput" class="c-search-form__label _mdl-layout">
                                    <input name="q" type="search" class="c-search-form__input" id="searchInput" placeholder="Search">
                                    <button type="submit" class="c-search-form__submit mdl-button mdl-js-button mdl-button--icon"><i class="material-icons">search</i></button>
                                </label>
                            </form>
                        
                                                
                                                    <div class="c-navbar__primary u-hide u-show@navbar">
                                <div class="_mdl-layout c-navbar__cta">
                                    <a class="mdl-button mdl-js-button mdl-button--raised mdl-button--no-shadow mdl-button--multi-line mdl-js-ripple-effect mdl-button--inverted c-navbar__submit" href="/for-authors/publish-your-research"   data-test-id="nav_submit_research"  ><i class="material-icons">file_upload</i>Submit your research</a>
                                </div>
                            </div>
                        

                                                
                        <span class="u-hide@navbar _mdl-layout u-nowrap">

                                                            <button type="button" class="mdl-button mdl-js-button mdl-js-ripple-effect mdl-button--icon c-navbar__toggle c-navbar__toggle--menu js-navbar-toggle" data-focus="#navbar_mob_search_input" data-toggle="navbarMenu" data-target="navbarMenu" aria-controls="navbarMenu" aria-expanded="false" aria-label="Toggle navigation"   data-test-id="nav_menu_search_mob"  ><i class="material-icons">search</i></button>
                            
                                                            <button class="mdl-button mdl-js-button mdl-js-ripple-effect mdl-button--icon mdl-button--multi-line c-navbar__toggle c-navbar__toggle--menu js-navbar-toggle" type="button" data-toggle="navbarMenu" data-target="navbarMenu" aria-controls="navbarMenu" aria-expanded="false" aria-label="Toggle navigation"   data-test-id="nav_menu_toggle_mob"  >
                                    <i class="material-icons c-navbar__toggle-open">menu</i>
                                    <i class="material-icons c-navbar__toggle-close">close</i>
                                </button>
                                                    </span>
                    </div>

                </div>
            </div>

                        
                            <div class="c-navbar__menu-row js-navbar-block is-collapsed" id="navbarMenu">

                                                                                                                                                
                                                                    
                                                                    
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        
                                            

                                                                
                                                                                                                                                                                                                                
                                            
                    <div class="c-navbar__menu-row-content">

                                                                            <div class="u-hide@navbar c-navbar__menu-bar-spacing">
                                <form action="/search" class="c-search-form js-search-form">
                                    <label for="navbar_mob_search_input" class="c-search-form__label _mdl-layout">
                                        <input id="navbar_mob_search_input" name="q" type="search" class="c-search-form__input" placeholder="Search">
                                        <button type="submit" class="c-search-form__submit mdl-button mdl-js-button mdl-button--icon"><i class="material-icons">search</i></button>
                                    </label>
                                </form>
                            </div>
                        
                        <div class="o-actions o-actions--middle">

                            <div class="o-actions__primary">

                                                                
    <ul class="c-menubar c-navbar__menu-bar js-main-menu"   id="main-menu"   role="menubar" aria-label="Main Navigation"  data-menu-group="navbar" >

        
            
                                                                
                                
                                
                                    <li role="none"
                        data-index="0"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                              ">

                        <a href="/browse/articles" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                                                    tabindex="0"
                              data-test-id="nav_browse"                              >Browse</a>

                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="1"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                              ">

                        <a href="/gateways" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                                                    tabindex="-1"
                              data-test-id="nav_gatewaysViewAndBrowse"                              >Gateways & Collections</a>

                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="2"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                               c-menubar__item--selected c-navbar__menu-bar-item--parent ">

                        <a href="#" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                         aria-haspopup="true" aria-expanded="false"                             tabindex="-1"
                              data-test-id="nav_for-authors"                              >How to Publish</a>

                                                    
    <ul class="c-menu js-menu
                is-collapsed                c-menubar__menu c-navbar__menu"
                  role="menu"
        aria-label="How to Publish">

        
            
                                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_submit-manuscript"                      href="/for-authors/publish-your-research"
                    role="menuitem"
                    tabindex="0">Submit your Research</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_my-submissions"                      href="/for-authors/my-submissions"
                    role="menuitem"
                    tabindex="-1">My Submissions</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_article-guidelines"                      href="/for-authors/article-guidelines"
                    role="menuitem"
                    tabindex="-1">Article Guidelines</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_article-guidelines-new-versions"                      href="/for-authors/article-guidelines-new-versions"
                    role="menuitem"
                    tabindex="-1">Article Guidelines (New Versions)</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_data-guidelines"                      href="/for-authors/data-guidelines"
                    role="menuitem"
                    tabindex="-1">Data Guidelines</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_asset-guidelines"                      href="/for-authors/posters-and-slides-guidelines"
                    role="menuitem"
                    tabindex="-1">Posters and Slides Guidelines</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_document-guidelines"                      href="/for-authors/document-guidelines"
                    role="menuitem"
                    tabindex="-1">Document Guidelines</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_article-processing-charges"                      href="/for-authors/article-processing-charges"
                    role="menuitem"
                    tabindex="-1">Article Processing Charges</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_finding-referees"                      href="/for-authors/tips-for-finding-referees"
                    role="menuitem"
                    tabindex="-1">Finding Article Reviewers</a>

                </li>

                        </ul>
                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="3"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                               c-menubar__item--selected c-navbar__menu-bar-item--parent ">

                        <a href="#" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                         aria-haspopup="true" aria-expanded="false"                             tabindex="-1"
                              data-test-id="nav_about-contact"                              >About</a>

                                                    
    <ul class="c-menu js-menu
                is-collapsed                c-menubar__menu c-navbar__menu"
                  role="menu"
        aria-label="About">

        
            
                                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_about-page"                      href="/about"
                    role="menuitem"
                    tabindex="0">How it Works</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_referee-guidelines"                      href="/for-referees/guidelines"
                    role="menuitem"
                    tabindex="-1">For Reviewers</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_advisoryPanel"                      href="/advisors"
                    role="menuitem"
                    tabindex="-1">Our Advisors</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_policy-page"                      href="/about/policies"
                    role="menuitem"
                    tabindex="-1">Policies</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_glossary-page"                      href="/glossary"
                    role="menuitem"
                    tabindex="-1">Glossary</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_faqs-page"                      href="/faqs"
                    role="menuitem"
                    tabindex="-1">FAQs</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              u-hide u-show@navbar"
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      u-hide u-show@navbar"
                                          data-test-id="nav_for-developers"                      href="/developers"
                    role="menuitem"
                    tabindex="-1">For Developers</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_newsroom-page"                      href="/newsroom"
                    role="menuitem"
                    tabindex="-1">Newsroom</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_contact-page"                      href="/contact"
                    role="menuitem"
                    tabindex="-1">Contact</a>

                </li>

                        </ul>
                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="4"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                              ">

                        <a href="https://blog.f1000.com/blogs/f1000research/" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                             target="_blank"                                                         tabindex="-1"
                              data-test-id="nav_blog"                              >Blog</a>

                                            </li>
                
            
        
    </ul>



                            </div>

                            <div class="o-actions__secondary">

                                                                
    <ul class="c-menubar c-navbar__menu-bar js-main-menu"   id="secondary-items"   role="menubar" aria-label="My Account"  data-menu-group="navbar" >

        
            
                                                                
                                
                                
                                    <li role="none"
                        data-index="0"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                               c-menubar__item--selected c-navbar__menu-bar-item--parent ">

                        <a href="#" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                         aria-haspopup="true" aria-expanded="false"                             tabindex="0"
                              data-test-id="nav_my-research"                              >My Research</a>

                                                    
    <ul class="c-menu js-menu
                is-collapsed                c-menubar__menu c-navbar__menu"
                  role="menu"
        aria-label="My Research">

        
            
                                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_my-submissions"                      href="/login?originalPath=/my/submissions"
                    role="menuitem"
                    tabindex="0">Submissions</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_my-email-alerts"                      href="/login?originalPath=/my/email-alerts"
                    role="menuitem"
                    tabindex="-1">Content and Tracking Alerts</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_my-user-details"                      href="/login?originalPath=/my/user-details"
                    role="menuitem"
                    tabindex="-1">My Details</a>

                </li>

                        </ul>
                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="1"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                              ">

                        <a href="/login?originalPath=/articles/9-680.html" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                                                    tabindex="-1"
                              data-test-id="nav_sign-in"                              >Sign In</a>

                                            </li>
                
            
        
    </ul>



                            </div>

                                                                                        <div class="_mdl-layout c-navbar__cta u-hide@navbar c-navbar__menu-bar-spacing">
                                    <a class="mdl-button mdl-js-button mdl-button--raised mdl-button--multi-line mdl-button--no-shadow mdl-js-ripple-effect mdl-button--inverted c-navbar__submit" href="/for-authors/publish-your-research"   data-test-id="nav_submit_research_mob"  ><i class="material-icons">file_upload</i>Submit your research</a>
                                </div>
                                                    </div>

                    </div>

                </div>
            
        </div>

    </div>

</nav>
                    </div>

        <div class="content-wrapper o-page__main row ">
            <div id="highlight-area" class="content ">
                





<div id=article-metadata class=hidden> <input type=hidden name=versionId value=26833 /> <input type=hidden id=articleId name=articleId value=24320 /> <input type=hidden id=xmlUrl value="/articles/9-680/v1/xml"/> <input type=hidden id=xmlFileName value="-9-680-v1.xml"> <input type=hidden id=article_uuid value=42c4b4ec-2cad-4876-a4ea-1277540a9d7e /> <input type=hidden id=referer value=""/> <input type=hidden id=meta-article-title value="Malaria vaccines targeting the pre-erythrocytic stage: a scoping review"/> <input type=hidden id=workspace-export-url value="https://sciwheel.com/work/api/import/external?doi=10.12688/f1000research.24320.1"/> <input type=hidden id=versionDoi value="10.12688/f1000research.24320.1"/> <input type=hidden id=usePmcStats value=true /> </div> <main class="o-wrapper p-article__wrapper js-wrapper"> <script type="application/ld+json">
{
  "@context": "https://schema.org",
  "@type": "ScholarlyArticle",
  "mainEntityOfPage": {
    "@type": "WebPage",
    "@id": "https://f1000research.com/articles/9-680"
  },
  "headline": "Malaria vaccines targeting the pre-erythrocytic stage: a scoping review",
  "datePublished": "2020-07-07T12:28:06",
  "dateModified": "2020-07-07T12:28:06",
  "author": [
    {
      "@type": "Person",
      "name": "Teresa Ogeto"
    },    {
      "@type": "Person",
      "name": "Ferdinand Ndubi"
    },    {
      "@type": "Person",
      "name": "Mary Murithi"
    },    {
      "@type": "Person",
      "name": "Richard Kagia"
    },    {
      "@type": "Person",
      "name": "Esbon Wambugu"
    },    {
      "@type": "Person",
      "name": "Titus Suge"
    },    {
      "@type": "Person",
      "name": "Carolyne Chepkirui"
    },    {
      "@type": "Person",
      "name": "Josephat Tonui"
    },    {
      "@type": "Person",
      "name": "Fiona Maiyo"
    },    {
      "@type": "Person",
      "name": "Lydia Momanyi"
    },    {
      "@type": "Person",
      "name": "Michael Walekhwa"
    }  ],
  "publisher": {
    "@type": "Organization",
    "name": "F1000Research",
    "logo": {
      "@type": "ImageObject",
      "url": "https://f1000research.com/img/AMP/F1000Research_image.png",
      "height": 480,
      "width": 60
    }
  },
  "image": {
    "@type": "ImageObject",
    "url": "https://f1000research.com/img/AMP/F1000Research_image.png",
    "height": 1200,
    "width": 150
  },
  "description": "Malaria is a deadly infectious parasitic disease that causes devastating morbidity and mortality globally. Despite being a public health concern, an effective vaccine for prevention of the disease remains elusive. Global efforts are exploring possible ways of developing and improving vaccines to counteract the complex nature in which Plasmodium falciparum evades the immune system. A number of vaccines have been developed in the past targeting the various parasitic life cycle stages. Transmission blocker vaccines, such as PpPf S25, target the parasite stages in the mosquito vector. However, these herd vaccines only protect the immunized population. Vaccines targeting blood-stage forms, such as the AMA-1 and MSP-1 vaccines, are challenged by the complex metabolic pathways of erythrocytes and merozoites. Vaccines targeting the pre-erythrocytic sporozoite stage remain the most promising approach thus far. Here, we systematically review the literature on pre-erythrocytic stage vaccines and on-going work in the field. Furthermore, we highlight gaps in current knowledge and point to potential areas of future work. Articles on pre-erythrocytic malaria vaccines were obtained from Google scholar, PubMed and Cochrane starting from the year 2010. Ten papers were reviewed. A number of vaccines were reviewed highlighting; the vaccine type, clinical phase of trial, population demographics, vaccine immunogenicity, efficacy and safety. The RTS,S vaccine is reportedly the most advanced, having been rolled out for phase III clinical trials in a number of malaria-endemic African countries. The pre-erythrocytic vaccines discussed have made milestones in clinical trials. Some of the challenges elicited may be addressed via screening for novel antigens, exploring suitable vaccine administration vehicles,&amp;shy; as well as using a combined multi-stage vaccine approach."
}
</script> <div class="o-layout o-layout--right-gutter"> <div id=article_secondary-column class="p-article__main o-layout__item u-font-size--legal u-2/3@article not-expanded "> <div class=float-left> <script type="application/ld+json">
  {
    "@context": "http://schema.org",
    "@type": "BreadcrumbList",
    "itemListElement": [
              {
          "@type": "ListItem",
          "position": "1",
          "item": {
            "@id": "https://f1000research.com/",
            "name": "Home"
          }
        },              {
          "@type": "ListItem",
          "position": "2",
          "item": {
            "@id": "https://f1000research.com/browse/articles",
            "name": "Browse"
          }
        },              {
          "@type": "ListItem",
          "position": "3",
          "item": {
            "@id": "https://f1000research.com/articles/9-680.html",
            "name": "Malaria vaccines targeting the pre-erythrocytic stage: a scoping review"
          }
        }          ]
  }
  </script> <div class="breadcrumbs js-breadcrumbs"> <a href="/" class=f1r-standard-link>Home</a> <span class=item_separator></span> <a href="/browse/articles" class=f1r-standard-link>Browse</a> <span class=item_separator></span> Malaria vaccines targeting the pre-erythrocytic stage: a scoping review </div> </div> <div class="article-badges-container u-mb--2"> <div class=crossmark-new> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js"></script> <a data-target=crossmark><img height=30 width=150 src="https://crossmark-cdn.crossref.org/widget/v2.0/logos/CROSSMARK_Color_horizontal.svg"/></a> </div> <div id=crossmark-dialog style="display: none;" title=""> <iframe id=crossmark-dialog-frame frameborder=0></iframe> </div> <div class=clearfix></div> </div> <div class=article-interaction-container> <div id=main-article-count-box class=article-count-box> <div class="article-metrics-wrapper metrics-icon-wrapper" data-version-id=26833 data-id=24320 data-downloads="" data-views="" data-scholar="10.12688/f1000research.24320.1" data-recommended="" data-doi="10.12688/f1000research.24320.1" data-f1r-ga-helper="Article Page Metrics (Desktop)"> <span class="metrics-on-browse article-metrics-icon f1r-icon icon-89_metrics"></span> <div class="count-title article-metrics-text">ALL Metrics</div> <div class=js-article-metrics-container></div> </div> <div> <div class=count-delimiter></div> <div title="Total views from F1000Research and PubMed Central"> <div class="count-container view-count js-views-count">-</div> <div class=count-title><span class="count-title-icon count-title-views-icon"></span>Views</div> </div> <div class=download-counts hidden> <div class=count-delimiter></div> <div title="Total downloads from F1000Research and PubMed Central"> <div class="count-container js-downloads-count"></div> <div class=count-title><span class="count-title-icon f1r-icon icon-76_download_file"></span>Downloads</div> </div> </div> </div> </div> <div id=main-article-interaction-box class="article-interaction-box has-control-tab"> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-102_download_pdf"></span> <a href="https://f1000research.com/articles/9-680/v1/pdf?article_uuid=42c4b4ec-2cad-4876-a4ea-1277540a9d7e" title="Download PDF" class="button-link download pdf-download-helper" target=_blank>Get PDF</a> </div> </div> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-103_download_xml"></span> <a id=download-xml href="#" class="button-link download" title="Download XML">Get XML</a> </div> </div> <div class="article-interaction-info article-page"> <div class="cite-article-popup-wrapper article-page-interaction-box"> <div class="article-interaction-button cite-article-button" title="Cite this article" data-windowref=cite-article-popup-24320-1> <span class="f1r-icon icon-82_quote"></span> <a href="#" class="button-link cite-article-popup-link" title="Cite Article">Cite</a> </div> <div id=cite-article-popup-24320-1 class="popup-window-wrapper is-hidden"> <div class=cite-popup-background></div> <div class="popup-window top-popup cite-this-article-box research-layout"> <div class="popup-window-title small cite-title">How to cite this article</div> <span id=cite-article-text-24320-1 data-test-id=copy-citation_text> <span class="article-title-and-info in-popup">Ogeto T, Ndubi F, Murithi M <em>et al.</em> Malaria vaccines targeting the pre-erythrocytic stage: a scoping review [version 1; peer review: awaiting peer review]</span>. <i>F1000Research</i> 2020, <b>9</b>:680 (<a class=new-orange href="https://doi.org/10.12688/f1000research.24320.1" target=_blank>https://doi.org/10.12688/f1000research.24320.1</a>) </span> <div class="popup-window-title small margin-top-20 margin-bottom-20 note"> <strong>NOTE:</strong> it is important to ensure the information in square brackets after the title is included in all citations of this article. </div> <div class=float-right> <button class="secondary no-fill orange-text-and-border margin-right-20 close-cite-popup uppercase">Close</button> <button id=copy-citation-details class="secondary orange copy-cite-article-version uppercase js-clipboard" title="Copy the current citation details to the clipboard." data-clipboard-target="#cite-article-text-24320-1" data-test-id=copy-citation_button>Copy Citation Details</button> </div> </div> </div> </div> </div> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-76_download_file"></span> <a id=export-citation href="#" class="button-link download" title="Export Citation">Export</a> </div> <div class="modal-window-wrapper is-hidden"> <div id=export-citation-popup class="modal-window padding-20"> <div class=modal-window-close-button></div> <div class=modal-window-title>Export Citation</div> <div class=modal-window-row> <div> <input type=radio name=export-citation-option value=WORKSPACE /> <span class=radio-label>Sciwheel</span> </div> <div> <input type=radio name=export-citation-option value=ENDNOTE /> <span class=radio-label>EndNote</span> </div> <div> <input type=radio name=export-citation-option value=REF_MANAGER /> <span class=radio-label>Ref. Manager</span> </div> <div> <input type=radio name=export-citation-option value=BIBTEX /> <span class=radio-label>Bibtex</span> </div> <div> <input type=radio name=export-citation-option value=PROCITE /> <span class=radio-label>ProCite</span> </div> <div> <input type=radio name=export-citation-option value=SENTE /> <span class=radio-label>Sente</span> </div> </div> <div class=modal-window-footer> <button class=general-white-orange-button id=export-citation-submit>EXPORT</button> </div> <div class=default-error style="display: none;">Select a format first</div> </div> </div> </div> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-90_track"></span> <a class="button-link track-article" data-article-id=24320 id=track-article-signin-24320 title="Receive updates on new activity such as publication of new versions, peer reviews or author responses." href="/login?originalPath=/trackArticle/24320?target=/articles/9-680.html">Track</a> </div> </div> <div class="article-interaction-info article-page"> <div class="article-interaction-button email-article"> <span class="f1r-icon icon-6_email"></span> <a href="#" class=button-link title="Email this article">Email</a> </div> <div class="email-article-version-container small-tooltip _chrome-fix"> <div class=close-icon><span class="f1r-icon icon-3_close_big"></span></div> <script src='https://www.recaptcha.net/recaptcha/api.js'></script> <form class="recommend-version-form research-layout"> <p>All fields are required.</p> <input name=versionId type=hidden value=26833 /> <input name=articleId type=hidden value=24320 /> <input name=senderName class="form-input-field reg-form" value="" type=text placeholder="Your name"/> <input name=senderEmail class="form-input-field reg-form margin-top" value="" type=text placeholder="Your email address"/> <textarea name=recipientEmails class="form-textarea-field ninetynine-percent-wide margin-top no-resize" placeholder="Recipient email address(es) (comma delimited)"></textarea> <input class="form-input-field reg-form margin-top" name=subject type=text value="Interesting article on F1000Research" placeholder=Subject /> <textarea name=message class="form-textarea-field reg-form margin-top no-resize">I thought this article from F1000Research (https://f1000research.com) would be of interest to you.</textarea> <div class="g-recaptcha margin-top" data-sitekey=6LcHqxoUAAAAANP3_0TzpGG6qFvl4DhbUcuRzw7W></div> <input value="" name=captcha type=hidden /> <p>A full article citation will be automatically included.</p> <p><img class="ticker-email-article-details hidden" src="/img/ticker.gif" alt=loading /></p> <button class="secondary orange margin-bottom" data-test-id=version_share_email_send>SEND EMAIL</button> <div class="orange-message margin-bottom is-hidden" data-test-id=version_share_email_message></div> </form> </div> </div> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-34_share"></span> <a href="#" class="button-link last addthis_button share-article" title="Share this article">Share</a> </div> </div> </div> <div id=article-interaction-control-tab class=article-interaction-control-tab> <div id=hide-article-interaction class=article-interaction-control title="Hide Toolbox">&#9644;</div> <div id=show-article-interaction class="article-interaction-control open" title="Show Toolbox">&#10010;</div> </div> </div> <div class="article-header-information article-page"> <div class="f1r-article-mobile article-heading-bar"></div> <div class="article-type article-display">Systematic Review </div> <div class="article-title-and-info article-view highlighted-article" id=anchor-title> <h1>Malaria vaccines targeting the pre-erythrocytic stage: a scoping review</h1><span class=other-info> [version 1; peer review: awaiting peer review]</span> </div> <div class=article-subtitle></div> <div class=f1r-article-desk> <div class="authors _mdl-layout"><span class="">Teresa Ogeto<sup>1</sup>,&nbsp;</span><span class="">Ferdinand Ndubi<sup>2</sup>,&nbsp;</span><span class="">Mary Murithi<sup>3</sup>,&nbsp;</span><a href="#" class=article-page-expand-authors>[...]&nbsp;</a><span class=article-page-hidden-authors>Richard Kagia<a href="https://orcid.org/0000-0002-0226-9754" target=_blank id=author-orcid-3><span class=orcid-logo-for-author-list></span></a><div class="mdl-tooltip mdl-tooltip--wider" for=author-orcid-3><span class=orcid-logo-for-author-list></span> https://orcid.org/0000-0002-0226-9754</div><sup>4</sup>,&nbsp;</span><span class=article-page-hidden-authors>Esbon Wambugu<a href="https://orcid.org/0000-0002-6783-0370" target=_blank id=author-orcid-4><span class=orcid-logo-for-author-list></span></a><div class="mdl-tooltip mdl-tooltip--wider" for=author-orcid-4><span class=orcid-logo-for-author-list></span> https://orcid.org/0000-0002-6783-0370</div><sup>4</sup>,&nbsp;</span><span class=article-page-hidden-authors>Titus Suge<sup>4</sup>,&nbsp;</span><span class=article-page-hidden-authors>Carolyne Chepkirui<a href="https://orcid.org/0000-0003-1159-5188" target=_blank id=author-orcid-6><span class=orcid-logo-for-author-list></span></a><div class="mdl-tooltip mdl-tooltip--wider" for=author-orcid-6><span class=orcid-logo-for-author-list></span> https://orcid.org/0000-0003-1159-5188</div><sup>5</sup>,&nbsp;</span><span class=article-page-hidden-authors>Josephat Tonui<sup>1</sup>,&nbsp;</span><span class="">Fiona Maiyo<sup>1</sup>,&nbsp;</span><span class="">Lydia Momanyi<sup>6</sup>,&nbsp;</span><span class=""><a href="mailto:walekhwam@gmail.com" title="Send email" class="cauthor research-layout"><span class='f1r-icon icon-6_email orange'></span><span>Michael Walekhwa</span></a><a href="https://orcid.org/0000-0003-1337-1284" target=_blank id=author-orcid-10><span class=orcid-logo-for-author-list></span></a><div class="mdl-tooltip mdl-tooltip--wider" for=author-orcid-10><span class=orcid-logo-for-author-list></span> https://orcid.org/0000-0003-1337-1284</div><sup>1</sup></span><span class="author-display-control article-page-expand-authors f1r-icon icon-20_plus_big"></span><span class="author-display-control article-page-hidden-authors f1r-icon icon-12_minus_big"></span></div> </div> <div class=f1r-article-mobile> <div class="authors _mdl-layout"><span class="">Teresa Ogeto<sup>1</sup>,&nbsp;</span><span class="">Ferdinand Ndubi<sup>2</sup>,&nbsp;</span><a href="#" class=article-page-expand-authors>[...]&nbsp;</a><span class=article-page-hidden-authors>Mary Murithi<sup>3</sup>,&nbsp;</span><span class=article-page-hidden-authors>Richard Kagia<a href="http://orcid.org/0000-0002-0226-9754" target=_blank id=mauthor-orcid-3><span class=orcid-logo-for-author-list></span></a><div class="mdl-tooltip mdl-tooltip--wider" for=mauthor-orcid-3><span class=orcid-logo-for-author-list></span> https://orcid.org/0000-0002-0226-9754</div><sup>4</sup>,&nbsp;</span><span class=article-page-hidden-authors>Esbon Wambugu<a href="http://orcid.org/0000-0002-6783-0370" target=_blank id=mauthor-orcid-4><span class=orcid-logo-for-author-list></span></a><div class="mdl-tooltip mdl-tooltip--wider" for=mauthor-orcid-4><span class=orcid-logo-for-author-list></span> https://orcid.org/0000-0002-6783-0370</div><sup>4</sup>,&nbsp;</span><span class=article-page-hidden-authors>Titus Suge<sup>4</sup>,&nbsp;</span><span class=article-page-hidden-authors>Carolyne Chepkirui<a href="http://orcid.org/0000-0003-1159-5188" target=_blank id=mauthor-orcid-6><span class=orcid-logo-for-author-list></span></a><div class="mdl-tooltip mdl-tooltip--wider" for=mauthor-orcid-6><span class=orcid-logo-for-author-list></span> https://orcid.org/0000-0003-1159-5188</div><sup>5</sup>,&nbsp;</span><span class=article-page-hidden-authors>Josephat Tonui<sup>1</sup>,&nbsp;</span><span class=article-page-hidden-authors>Fiona Maiyo<sup>1</sup>,&nbsp;</span><span class="">Lydia Momanyi<sup>6</sup>,&nbsp;</span><span class=""><a href="mailto:walekhwam@gmail.com" title="Send email" class="cauthor research-layout"><span class='f1r-icon icon-6_email orange'></span><span>Michael Walekhwa</span></a><a href="http://orcid.org/0000-0003-1337-1284" target=_blank id=mauthor-orcid-10><span class=orcid-logo-for-author-list></span></a><div class="mdl-tooltip mdl-tooltip--wider" for=mauthor-orcid-10><span class=orcid-logo-for-author-list></span> https://orcid.org/0000-0003-1337-1284</div><sup>1</sup></span><span class="author-display-control article-page-expand-authors f1r-icon icon-20_plus_big"></span><span class="author-display-control article-page-hidden-authors f1r-icon icon-12_minus_big"></span></div> </div> <div class=f1r-article-mobile> <div class=article-pubinfo-mobile> PUBLISHED 07 Jul 2020 </div> </div> <span class=Z3988 title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info:ofi/fmt:kev:mtx:journal&amp;rft_id=info:doi/10.12688%2Ff1000research.24320.1"></span> <div class=f1r-article-desk> <div class="contracted-details first"> <a href="#" class="contracted-details-label author-affiliations"><span class=contracted></span>Author details</a> <a href="#" class=section-title>Author details</a> <span class="f1r-icon icon-14_more_small section-control"></span> <span class="f1r-icon icon-10_less_small section-control"></span> <div class="expanded-details affiliations is-hidden"> <sup>1</sup> Department of Biomedical Sciences, Kabarak University, Nakuru, Kenya, 20157, Kenya<br/> <sup>2</sup> Department of Pharmaceutical Chemistry &amp; Pharmaceutics, Kabarak University, Nakuru, Kenya, 20157, Kenya<br/> <sup>3</sup> Department of Pre-Clinical, Kabarak University, Nakuru, Kenya, 20157, Kenya<br/> <sup>4</sup> Pharmacology &amp; Pharmacognosy, Kabarak University, Nakuru, Kenya, 20157, Kenya<br/> <sup>5</sup> Department of Physical &amp; Biological Sciences, Kabarak University, Nakuru, Kenya, 20157, Kenya<br/> <sup>6</sup> Department of Pharmacy, Nakuru Level V Hospital, Nakuru, Kenya, 20157, Kenya<br/> <p> <div class=margin-bottom> Teresa Ogeto <br/> <span>Roles: </span> Methodology, Writing  Original Draft Preparation </div> <div class=margin-bottom> Ferdinand Ndubi <br/> <span>Roles: </span> Conceptualization, Writing  Original Draft Preparation </div> <div class=margin-bottom> Mary Murithi <br/> <span>Roles: </span> Conceptualization, Methodology, Writing  Original Draft Preparation </div> <div class=margin-bottom> Richard Kagia <br/> <span>Roles: </span> Conceptualization, Writing  Original Draft Preparation </div> <div class=margin-bottom> Esbon Wambugu <br/> <span>Roles: </span> Formal Analysis, Writing  Original Draft Preparation </div> <div class=margin-bottom> Titus Suge <br/> <span>Roles: </span> Resources, Writing  Review & Editing </div> <div class=margin-bottom> Carolyne Chepkirui <br/> <span>Roles: </span> Conceptualization, Writing  Review & Editing </div> <div class=margin-bottom> Josephat Tonui <br/> <span>Roles: </span> Conceptualization, Formal Analysis, Writing  Original Draft Preparation </div> <div class=margin-bottom> Fiona Maiyo <br/> <span>Roles: </span> Formal Analysis, Methodology, Writing  Review & Editing </div> <div class=margin-bottom> Lydia Momanyi <br/> <span>Roles: </span> Conceptualization, Resources, Writing  Review & Editing </div> <div class=margin-bottom> Michael Walekhwa <br/> <span>Roles: </span> Conceptualization, Project Administration, Writing  Original Draft Preparation, Writing  Review & Editing </div> </p> </div> </div> </div> <div class=f1r-article-mobile> <div class="article-page-section-box margin-bottom-40 research-layout"> <span class=box-title> <span class="f1r-icon icon-85_peer_review"></span> OPEN PEER REVIEW </span> <div class="status-row referee-reports-container"> REVIEWER STATUS <span class=status-icons> <em>AWAITING PEER REVIEW</em> </span> </div> </div> </div> </div> <h2 class="article-headings article-page-abstract" id=anchor-abstract> <span class="f1r-article-mobile-inline abstract-heading-border"></span> Abstract </h2> <div class="article-abstract article-page-general-text-mobile research-layout"> <div class="abstract-text is-expanded"> Malaria is a deadly infectious parasitic disease that causes devastating morbidity and mortality globally. Despite being a public health concern, an effective vaccine for prevention of the disease remains elusive. Global efforts are exploring possible ways of developing and improving vaccines to counteract the complex nature in which <i>Plasmodium falciparum </i>evades the immune system. A number of vaccines have been developed in the past targeting the various parasitic life cycle stages. Transmission blocker vaccines, such as <i>PpPf S25,</i> target the parasite stages in the mosquito vector. However, these herd vaccines only protect the immunized population. Vaccines targeting blood-stage forms, such as the <i>AMA-1</i> and <i>MSP-1</i> vaccines, are challenged by the complex metabolic pathways of erythrocytes and merozoites. Vaccines targeting the pre-erythrocytic sporozoite stage remain the most promising approach thus far. Here, we systematically review the literature on pre-erythrocytic stage vaccines and on-going work in the field. Furthermore, we highlight gaps in current knowledge and point to potential areas of future work. Articles on pre-erythrocytic malaria vaccines were obtained from Google scholar, PubMed and Cochrane starting from the year 2010. Ten papers were reviewed. A number of vaccines were reviewed highlighting; the vaccine type, clinical phase of trial, population demographics, vaccine immunogenicity, efficacy and safety. The <i>RTS,S</i> vaccine is reportedly the most advanced, having been rolled out for phase III clinical trials in a number of malaria-endemic African countries. The pre-erythrocytic vaccines discussed have made milestones in clinical trials. Some of the challenges elicited may be addressed via screening for novel antigens, exploring suitable vaccine administration vehicles,&shy; as well as using a combined multi-stage vaccine approach. </div> <div class=abstract-for-mobile> <div class="margin-top-30 padding-bottom-30 research-layout is-centered"> <button class="primary orange-text white-bg bigger-text abstract-expand-button-mobile with-border show" style="display: none;"> READ ALL <span class="f1r-icon icon-14_more_small orange vmiddle big"></span> </button> <button class="primary orange-text white-bg bigger-text abstract-expand-button-mobile with-border hide"> READ LESS <span class="f1r-icon icon-10_less_small orange vmiddle big"></span> </button> </div> </div> </div> <div class=clearfix></div> <div class="article-context no-divider"> <div class="article-abstract article-page-general-text-mobile research-layout generated-article-body"> <h2 class=main-title>Keywords</h2> <p class="u-mb--0 u-pb--2"> Malaria, Pre-erythrocytic, Plasmodium falciparum, Vaccines, Sporozoites, efficacy </p> </div> </div> <div class=article-information> <span class="info-separation padding-bottom"> <div id=corresponding-author-icon class="email-icon float-left"> <span class="f1r-icon icon-6_email orange"></span> <div id=corresponding-author-window class="margin-top-20 popup-window-wrapper is-hidden"> <div class="popup-window corresponding-authors-popup"> <div class=corresponding-author-container> <div class="popup-window-title small">Corresponding Author(s)</div> <div class=authors> Michael Walekhwa (<a href="mailto:walekhwam@gmail.com">walekhwam@gmail.com</a>) </div> </div> <div class="margin-top margin-bottom float-left"> <button id=close-popup-window class=general-white-orange-button>Close</button> </div> </div> </div> </div> <span class="icon-text float-left" data-test-id=box-corresponding-author> <b>Corresponding author:</b> Michael Walekhwa </span> <div class=clearfix></div> </span> <span class="info-separation padding-bottom competing-interests-display"> <span class=competing-interests-title>Competing interests:</span> No competing interests were disclosed. </span> <div class="info-separation padding-bottom grant-information-display"> <span class=grant-information-title>Grant information:</span> The author(s) declared that no grants were involved in supporting this work. </div> <span class="f1r-article-desk info-separation padding-bottom"> <span class="copywrite-icon float-left"> <span class="f1r-icon icon-100_open_access"></span> </span> <span class="icon-text float-left" data-test-id=box-copyright-text> <b>Copyright:</b>&nbsp;  2020 Ogeto T <em>et al</em>. This is an open access article distributed under the terms of the <a href="http://creativecommons.org/licenses/by/4.0/" target=_blank data-test-id=box-licence-link>Creative Commons Attribution License</a>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. </span> <div class=clearfix></div> </span> <span class="info-separation padding-bottom" data-test-id=box-how-to-cite> <b>How to cite:</b> <span class="article-title-and-info in-article-box"> Ogeto T, Ndubi F, Murithi M <em>et al.</em> Malaria vaccines targeting the pre-erythrocytic stage: a scoping review [version 1; peer review: awaiting peer review]</span>. <i>F1000Research</i> 2020, <b>9</b>:680 (<a href="https://doi.org/10.12688/f1000research.24320.1" target=_blank>https://doi.org/10.12688/f1000research.24320.1</a>) </span> <span class=info-separation data-test-id=box-first-published><b>First published:</b> 07 Jul 2020, <b>9</b>:680 (<a href="https://doi.org/10.12688/f1000research.24320.1" target=_blank>https://doi.org/10.12688/f1000research.24320.1</a>)</span> <span class=info-separation data-test-id=box-latest-published><b>Latest published:</b> 07 Jul 2020, <b>9</b>:680 (<a href="https://doi.org/10.12688/f1000research.24320.1" target=_blank>https://doi.org/10.12688/f1000research.24320.1</a>)</span> </div> <div class=clearfix></div> <div id=article-context class=article-context> <div id=article1-body class=generated-article-body><h2 class=main-title id=d9025e324>Introduction</h2><p class="" id=d9025e327>Malaria, a disease commonly found in the tropics and subtropics is caused by parasites of the genus <i>Plasmodium</i> whereby <i>P. falciparum</i> causes the greatest disease burden. In 2018, it was estimated to have caused 228 million cases globally, out of which 93% (213 million) occurred in Africa<sup><a href="#ref-1">1</a></sup>. In Kenya, malaria is a major public health concern causing 6.7 million cases and 4000 mortalities in children annually<sup><a href="#ref-2">2</a>,<a href="#ref-3">3</a></sup>. Various community and facility interventional strategies, such as insecticide treated mosquito nets, indoor residual spraying, repellents and chemotherapy have significantly reduced the disease burden over the last decade<sup><a href="#ref-4">4</a></sup>. However, these strategies are limited in their efficacy; hence elimination of the disease is unlikely without an effective vaccine<sup><a href="#ref-5">5</a></sup>. Consequently, an effective vaccine conferring high protective efficacy is required to combat the disease.</p><p class="" id=d9025e356>To date, a number of vaccines have been developed and are at various stages of clinical trials. These vaccines target specific stage(s) of the parasite life cycle, such as pre-erythrocytic (liver-stage), erythrocytic (blood-stage) and gametocytes<sup><a href="#ref-6">6</a></sup>. The pre-erythrocytic vaccines (<i>RTS,S, PfSPZ, TRAP, PP</i>) that target the sporozoites have proved to be the most efficacious of these<sup><a href="#ref-7">7</a></sup>. Their superiority is founded primarily on the premise that the sporozoites harbour less antigens and are thus easily targeted by an appropriate vaccine. This results in reduced merozoite production thereby rendering the blood stage immune responses superior<sup><a href="#ref-8">8</a></sup>. The pre-erythrocytic stage is however faced with the challenge of culturing sporozoites <i>in vitro</i>, making it difficult to explore novel antigens<sup><a href="#ref-9">9</a></sup>.</p><p class="" id=d9025e382>The <i>RTS,S</i> vaccine, which has progressed to phase III clinical trials, has reportedly been found to be safe and immunogenic when tested in African children in malaria endemic regions such as Kenya and Tanzania<sup><a href="#ref-10">10</a>,<a href="#ref-11">11</a></sup>. However, trials of this vaccine done in Africa have revealed low efficacy levels. A study done by Olotu et al (2016), on children aged 517 months immunized with <i>RTS,S/AS01A</i> vaccine (cases) and rabies vaccine (controls), showed efficacy of 27% against first episode of clinical malaria<sup><a href="#ref-11">11</a></sup>. Radiation-attenuated sporozoites (RAS) delivered through the bite of an infected mosquito was 100% protective in humans<sup><a href="#ref-9">9</a></sup>. An irradiated <i>P. falciparum</i> sporozoites (<i>PfSPZ</i>) vaccine administered via intravenous injection also resulted in 100% protection in humans<sup><a href="#ref-12">12</a></sup>. Other pre-erythrocytic vaccines that have so far been tested in humans include the thrombospondin related anonymous protein (<i>TRAP</i>), multi-epitope thrombospondin related adhesion protein (<i>ME-TRAP)</i> and polyprotein (PP) vaccines<sup><a href="#ref-13">13</a>,<a href="#ref-14">14</a></sup>.</p><p class="" id=d9025e430>Despite the numerous interventions towards eliminating malaria, the parasite remains elusive. Vaccines remain to be the only hope to combat the disease. Therefore, efforts to understand <i>P. falciparum</i> biology and cross-talk mechanisms repressing the host immune response to an active infection are continuously being sought. In this review, we focus on milestones made on the pre-erythrocytic malaria vaccines in the last decade. We further highlight the challenges, immunogenicity and efficacy of these vaccines. Studies included mainly the <i>RTS,S</i> vaccine whose clinical trials were carried out in Africa, a malaria endemic region.</p></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d9025e442>Methods</h2><p class="" id=d9025e445>This review was done according to Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA)<sup><a href="#ref-15">15</a></sup>. Articles included were those that had the relevance of the subject of malaria vaccine.</p><div class=section><a name=d9025e452 class=n-a></a><h3 class=section-title>Sources and search strategy</h3><p class="" id=d9025e457>Google Scholar, Cochrane and PubMed were the sources of articles. The search terminologies used were pre-erythrocytic malaria vaccines and malaria vaccines. An advanced search strategy in Google Scholar was done to return articles with all the words pre-erythrocytic and malaria vaccines in their titles. The exact phrases captured in the article titles were pre-erythrocytic malaria vaccines or malaria vaccines. Article titles without the words review or meta-analysis or expert opinion or models dated between 20102020 were retrieved. The last search in the databases was done on 24<sup>th</sup> April 2020.</p></div><div class=section><a name=d9025e464 class=n-a></a><h3 class=section-title>Eligibility criteria</h3><p class="" id=d9025e469>Clinical trials were the only article type considered; reviews, meta-analysis, expert opinions, in vitro studies, mathematical and computer modeling studies were excluded. Articles published in English in the last ten years (20102020) were considered since promising milestones have been achieved in the last 10 years.</p></div><div class=section><a name=d9025e473 class=n-a></a><h3 class=section-title>Selection of articles</h3><p class="" id=d9025e478>To identify the suitability of the article to be included, the titles, abstracts, year of publication and type of study were considered. The papers were screened for eligibility by two reviewers and disagreements were resolved by consensus.</p></div><div class=section><a name=d9025e483 class=n-a></a><h3 class=section-title>Data extraction</h3><p class="" id=d9025e488>Relevant data was extracted from the included studies based on the type of the vaccine, study design, the clinical trial phase, the mode of vaccine administration, efficacy and safety profile, as well as related adverse events. Other important relevant information, such as the experimental procedures, were also evaluated for each study.</p></div></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d9025e495>Results</h2><p class="" id=d9025e498>In total, 17 articles were obtained from Google scholar, 7 from Cochrane and 231 from PubMed. After duplicate removal and screening, 10 articles were considered as meeting the criteria (<a href="#f1">Figure 1</a>).</p><a name=f1 class=n-a></a><div class="fig panel clearfix"><a target=_blank href="https://f1000researchdata.s3.amazonaws.com/manuscripts/26833/d8409ec0-3368-4855-a077-1045d2144ba2_figure1.gif"><img alt="d8409ec0-3368-4855-a077-1045d2144ba2_figure1.gif" src="https://f1000researchdata.s3.amazonaws.com/manuscripts/26833/d8409ec0-3368-4855-a077-1045d2144ba2_figure1.gif"></a><div class=caption><h3>Figure 1. PRISMA flow diagram for screening inclusion and exclusion of studies.</h3></div></div><p class="" id=d9025e518><a href="#T1">Table 1</a> exhibits the characteristics of the 10 articles that were included.</p><a name=T1 class=n-a></a><div class="table-wrap panel clearfix"><div class=caption><h3>Table 1. Articles (n=10) included in a scoping review of literature on the status of current malaria vaccines.</h3></div><table xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class=article-table frame=below><a name=d9025e534 class=n-a></a><thead><a name=d9025e536 class=n-a></a><tr><a name=d9025e538 class=n-a></a><th align=center colspan=1 rowspan=1 valign=top><a name=d9025e540 class=n-a></a>Vaccine type</th><th align=center colspan=1 rowspan=1 valign=top><a name=d9025e543 class=n-a></a>Study details</th><th align=center colspan=1 rowspan=1 valign=top><a name=d9025e546 class=n-a></a>Findings/Results</th><th align=center colspan=1 rowspan=1 valign=top><a name=d9025e549 class=n-a></a>Reference</th></tr></thead><tbody><a name=d9025e554 class=n-a></a><tr><a name=d9025e556 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d9025e558 class=n-a></a><b>Radiation attenuated</b><br class=br><b>sporozoite vaccine</b></td><td align=left colspan=1 rowspan=1 valign=top><a name=d9025e565 class=n-a></a>&nbsp;&nbsp;&nbsp;The vaccine was administered by mosquito bites to true<br class=br>immunized cohorts;<br class=br><br class=br>&nbsp;&nbsp;&nbsp;Peripheral blood mononuclear cells and plasma samples<br class=br>collected from 10 subjects before and after immunization<br class=br>were used;<br class=br><br class=br>&nbsp;&nbsp;&nbsp;Negative control group were subjects administered with<br class=br>irradiated non-infected mosquito bites and true immunized<br class=br>subjects were challenged after five, six and seven<br class=br>immunizing doses from bites by non-irradiated mosquitoes<br class=br>carrying infectious sporozoites.</td><td align=left colspan=1 rowspan=1 valign=top><a name=d9025e589 class=n-a></a>&nbsp;&nbsp;&nbsp;A total of 151 recombinant proteins (RPs) were observed, 131 of which<br class=br>were fully expressed;<br class=br><br class=br> &nbsp;&nbsp;&nbsp;Of the 151 RPs, 27 were reactive with Western Blots (WBs) when<br class=br>probed with the radiation-attenuated sporozoites (RAS) plasma. The<br class=br>27 RPs were selected for further profiling and characterization;<br class=br><br class=br> &nbsp;&nbsp;&nbsp;Protein P<i>f</i>78 initially recognized by RAS plasma pool was<br class=br>subsequently not reactive with WBs and was therefore excluded from<br class=br>the initial 27 RPs;<br class=br><br class=br>&nbsp;&nbsp;&nbsp;Six of the 27 RPs (antigens) failed to induce production of the required<br class=br>threshold of antibodies (Abs) while the remaining 21 were seropositive<br class=br>with sporozoites;<br class=br><br class=br> &nbsp;&nbsp;&nbsp;15 of the 21 RPs were positive with 7 day liver stage infection while 13<br class=br>were positive with blood stage infection and;<br class=br><br class=br> &nbsp;&nbsp;&nbsp;T-cell immune responses triggered by RAS immunization protected<br class=br>5 subjects against controlled human malaria infection (CHMI) when<br class=br>assayed by ELISPOT.</td><td align=center colspan=1 rowspan=1 valign=top><a name=d9025e633 class=n-a></a><a href="#ref-9">9</a></td></tr><tr><a name=d9025e638 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d9025e640 class=n-a></a><b><i>RTS,S/ASO</i>: Sub-unit</b><br class=br><b>vaccine</b></td><td align=left colspan=1 rowspan=1 valign=top><a name=d9025e649 class=n-a></a>&nbsp;&nbsp;&nbsp;The vaccine confers pre-erythrocytic immunity and is based<br class=br>on circumspozoite proteins;<br class=br><br class=br> &nbsp;&nbsp;&nbsp;A total of 894 children aged between 517 months<br class=br>were randomized into 2 groups in the ratio of 1:1 to receive<br class=br>3 doses of <i>RTS, S/AS0<sub>E</sub></i> or rabies vaccine (CG) at intervals of<br class=br>1 month.<br class=br><br class=br> &nbsp;&nbsp;&nbsp;Blood samples from study subjects were collected before<br class=br>vaccination and at 1, 8 and 12 months after the 3<sup>rd</sup> dose of<br class=br>vaccine;<br class=br><br class=br>&nbsp;&nbsp;&nbsp;Serum samples were tested on ELISA for presence of<br class=br>human IgG Abs against <i>P</i>. <i>falciparum</i> antigens.</td><td align=left colspan=1 rowspan=1 valign=top><a name=d9025e691 class=n-a></a>&nbsp;&nbsp;&nbsp;For <i>AMA-1, EBA-175</i> and <i>MSP-1<sub>42</sub></i>, Ab levels were highest in youngest<br class=br>subjects and older children;<br class=br><br class=br>&nbsp;&nbsp;&nbsp;Vaccination with <i>RTS, S/AS0<sub>E</sub></i> was associated with declines in Ab<br class=br>concentration;<br class=br><br class=br>&nbsp;&nbsp;&nbsp;Infection with clinical malaria episode during 3 months before<br class=br>assaying for Ab levels was associated with 10 fold higher levels of Ab<br class=br>concentration;<br class=br><br class=br>&nbsp;&nbsp;&nbsp;When adjusted for vaccination group, there was a positive association<br class=br>between increasing Ab concentration and risk of clinical malaria for<br class=br><i>AMA-1, MSP-1<sub>42</sub></i> and <i>EBA-175;</i><br class=br><br class=br>&nbsp;&nbsp;&nbsp;Ab concentrations were higher in the higher transmission area and<br class=br>a tenfold increase in Ab concentration was associated with a 13%<br class=br>decrease in the risk of clinical malaria.</td><td align=center colspan=1 rowspan=1 valign=top><a name=d9025e744 class=n-a></a><a href="#ref-8">8</a></td></tr><tr><a name=d9025e749 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d9025e751 class=n-a></a><b><i>PFSPZ</i>: Pf sporozoite</b><br class=br><b>attenuated vaccine</b></td><td align=left colspan=1 rowspan=1 valign=top><a name=d9025e760 class=n-a></a>&nbsp;&nbsp;&nbsp;Open label, to asses efficacy of <i>PFSPZ</i> administered by DVI<br class=br>in 3 (weeks 0,8 and 16) and 5 (weeks 0, 4, 8, 12 and 20)<br class=br>dose regimens;<br class=br><br class=br>&nbsp;&nbsp;&nbsp;Subjects were followed up after vaccine injection on days 2,<br class=br>7 and 14 to assess occurrence of any adverse events;<br class=br><br class=br>&nbsp;&nbsp;&nbsp;Number of <i>PFSPZ</i>/dose, number of doses and intervals<br class=br>between vaccines doses were altered;<br class=br><br class=br>&nbsp;&nbsp;&nbsp;Assessment of protection was done at week 3 and 24 after<br class=br>administration of the last dose of the vaccine;<br class=br><br class=br>&nbsp;&nbsp;&nbsp;The assessment was against both homologous and<br class=br>heterologous Pf parasites;<br class=br><br class=br>&nbsp;&nbsp;&nbsp;Efficiency and tolerability of direct venous inoculation (DVI)<br class=br>of <i>PFSPZ</i> was also assessed.</td><td align=left colspan=1 rowspan=1 valign=top><a name=d9025e803 class=n-a></a>&nbsp;&nbsp;&nbsp;Short period protection for both heterologous and homologous CHMI<br class=br>was over 80%;<br class=br><br class=br> &nbsp;&nbsp;&nbsp;Three weeks after completion of the last dose of <i>PFSPZ,</i> 92% of<br class=br>subjects vaccinated with 1.35  10<sup>6</sup> amount in a 5 dose plan and 87%<br class=br>of the subjects vaccinated with 1.35  10<sup>6</sup> amount in a 3 dose plan<br class=br>were protected against homologous CHMI;<br class=br><br class=br>&nbsp;&nbsp;&nbsp;The trial gave evidence that the vaccine gave short term protection<br class=br>against heterologous CHMI;<br class=br><br class=br> &nbsp;&nbsp;&nbsp;24 weeks after completion of the last vaccine dose, 70% and 57%<br class=br>of subjects immunized with the 3-dose and 5-dose of <i>PFSPZ,</i> were<br class=br>protected against homologous CHMI;<br class=br><br class=br>&nbsp;&nbsp;&nbsp;10% of subjects administered with 5-dose plan of <i>PFSPZ</i> were<br class=br>protected against heterologous CHMI;<br class=br><br class=br>&nbsp;&nbsp;&nbsp;<i>PFSPZ</i> vaccine was well tolerated and safe among the immunized<br class=br>subjects;Administration by DVI was most tolerated as compared to<br class=br>other traditional routes.</td><td align=center colspan=1 rowspan=1 valign=top><a name=d9025e863 class=n-a></a><a href="#ref-12">12</a></td></tr><tr><a name=d9025e868 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d9025e870 class=n-a></a><b><i>RTS,S/ASO</i>: Sub-unit</b><br class=br><b>vaccine</b></td><td align=left colspan=1 rowspan=1 valign=top><a name=d9025e879 class=n-a></a>&nbsp;&nbsp;&nbsp;A total of 15,460 children aged 612 weeks and 517 months<br class=br>were enrolled;<br class=br><br class=br> &nbsp;&nbsp;&nbsp;Children in each age category were further classified into<br class=br>3 study groups: the first group received three doses of<br class=br>the vaccine at intervals of 1 month plus a booster dose at<br class=br>18 months; the 2<sup>nd</sup> group received 3 doses of the vaccine<br class=br>at intervals of 1 month but were not given a booster dose<br class=br>at 18 months and; the 3<sup>rd</sup> group received a non-malaria<br class=br>comparator (control) vaccine;<br class=br><br class=br> &nbsp;&nbsp;&nbsp;The vaccine targets circumsporozoite proteins and is<br class=br>administered with adjuvants (<i>AS0<sub>1</sub> or ASO<sub>2</sub></i>);<br class=br><br class=br>&nbsp;&nbsp;&nbsp;Stage of vaccine: clinical trials;<br class=br><br class=br>&nbsp;&nbsp;&nbsp;Evaluated efficacy, safety, reactogenicity and<br class=br>immunogenicity of the vaccine across seven countries in<br class=br>Africa;<br class=br><br class=br>&nbsp;&nbsp;&nbsp;Presented vaccine efficacy against both clinical and severe<br class=br>forms of malaria in the older age category after 12 months<br class=br>of follow-up;<br class=br><br class=br>&nbsp;&nbsp;&nbsp;Antibody levels were assayed on ELISA;<br class=br><br class=br>&nbsp;&nbsp;&nbsp;Randomized controlled double blind trial design.</td><td align=left colspan=1 rowspan=1 valign=top><a name=d9025e945 class=n-a></a>&nbsp;&nbsp;&nbsp;The vaccines side effect profile was acceptable;<br class=br><br class=br>&nbsp;&nbsp;&nbsp;It could be administered safely together with other childhood vaccines<br class=br>starting at 6 weeks after birth;<br class=br><br class=br>&nbsp;&nbsp;&nbsp;The vaccine was immunogenic against both clinical and severe forms<br class=br>of malaria in children who were at least six weeks or older;<br class=br><br class=br> &nbsp;&nbsp;&nbsp;Incidences of both severe and clinical forms of malaria meeting the<br class=br>primary case definition after 12 months of follow-up among the older<br class=br>age category was 0.44 per/person/year in the <i>RTS, S/AS0<sub>1</sub></i> group<br class=br>while: it was 0.83 per/person/year in the control group (CG);<br class=br><br class=br>&nbsp;&nbsp;&nbsp;Vaccine efficacy against both forms of malaria was 55.1% at 95%<br class=br>confidence interval (CI);<br class=br><br class=br>&nbsp;&nbsp;&nbsp;Serious adverse events were observed in 17.6% at (95% CI, 16.7 to<br class=br>18.6) among subjects in the older age category in the RTS, S/AS01<br class=br>group while; 21.6% at (95% CI, 20.1 to 23.1);<br class=br><br class=br>&nbsp;&nbsp;&nbsp;About 0.9% (95% CI, 0.7 to 1.2) of the older category subjects who<br class=br>received the RTS, S/AS01 vaccine died while; 0.9% (95% CI, 0.6 to<br class=br>1.4) in the control group died;<br class=br><br class=br> &nbsp;&nbsp;&nbsp;Cases of meningitis and other adverse events were reported more in<br class=br>the <i>RTS, S/AS0<sub>1</sub></i> group than in the control group;<br class=br><br class=br>&nbsp;&nbsp;&nbsp;The geometric mean titer (GMT) of anti-circumsporozoite antibodies<br class=br>were low at enrolment but escalated to 99.9% in the <i>RTS, S/AS0<sub>1</sub></i><br class=br>group 1 month after administration of the 3<sup>rd</sup> dose.</td><td align=center colspan=1 rowspan=1 valign=top><a name=d9025e1019 class=n-a></a><a href="#ref-17">17</a></td></tr><tr><a name=d9025e1024 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d9025e1026 class=n-a></a><b><i>RTS, S</i> and <i>TRAP</i></b><br class=br><b>with ASO<sub>2</sub> adjuvants:</b><br class=br><b>Sub-unit vaccine</b></td><td align=left colspan=1 rowspan=1 valign=top><a name=d9025e1043 class=n-a></a>&nbsp;&nbsp;&nbsp;Phase 1 trials was conducted in both male and female<br class=br>subjects between the ages 1850 years, while phase 2 trials<br class=br>were conducted among male and female subjects between<br class=br>ages 1845 years and who had no history of malaria or<br class=br>injection of an investigative malaria vaccine;<br class=br><br class=br>&nbsp;&nbsp;&nbsp;In both trials, subjects were to be sero-negative for <i>HBsAg</i><br class=br>and hepatitis C;<br class=br><br class=br>&nbsp;&nbsp;&nbsp;In phase I trial, subjects were randomized into three groups<br class=br>as follows: <i>RTS, S/AS0<sub>2</sub>, TRAP/AS0<sub>2</sub></i> and <i>RTS, S/AS0<sub>2</sub>/TRAP/</i><br class=br><i>AS0<sub>2</sub></i> in the ratio of 1:1:2. The vaccines were administered at<br class=br>0, 1 and 6 months;<br class=br><br class=br>&nbsp;&nbsp;&nbsp;Phase II trial was a double blind. Subjects were classified<br class=br>in to 2 cohorts: cohort 1 received sporozoite challenge after<br class=br>2 doses while cohort 2 was to receive sporozoite challenge<br class=br>after 3 doses. However, because of poor protective<br class=br>exhibited in cohort 1, cohort 2 subjects were not enrolled;<br class=br><br class=br>&nbsp;&nbsp;&nbsp;Cohort 1 subjects were further randomized to receive: <i>RTS,</i><br class=br><i>S + TRAP/ASO<sub>2</sub></i> or <i>TRAP/ASO<sub>2</sub></i> in the ratio of 2:5:1 at 0 and 1<br class=br>months. The sporozoite challenge was then done at 7 to 30<br class=br>days after completing the second dose.</td><td align=left colspan=1 rowspan=1 valign=top><a name=d9025e1122 class=n-a></a>&nbsp;&nbsp;&nbsp;The most reported undesirable events were a transient pain at the<br class=br>site of injection, redness and swelling for all groups. No biochemical,<br class=br>hematological and abnormalities associated with urine were reported<br class=br>for during all trials;<br class=br><br class=br> &nbsp;&nbsp;&nbsp;There were no anti-circumsporozoite antibodies (anti-CS Abs)<br class=br>pre-vaccination. After immunization, geometric mean titers (GMTs)<br class=br>escalated at every time point especially for <i>RTS, S + TRAP/AS0<sub>2</sub>.</i><br class=br><br class=br> &nbsp;&nbsp;&nbsp;Anti-<i>TRAP</i> GMTs escalated after subsequent doses during the phase 1<br class=br>trial and decreased 6 months after the 3<sup>rd</sup> dose;<br class=br><br class=br>&nbsp;&nbsp;&nbsp;During the 2<sup>nd</sup> phase, the highest GMT was reported after completion<br class=br>of the 2<sup>nd</sup> dose for both RTS,S and TRAP/AS0<sub>2</sub>;<br class=br><br class=br>&nbsp;&nbsp;&nbsp;Significant elevations in levels of IFN- and IL-5 as well as IL-4<br class=br>were observed after the 2<sup>nd</sup> doses for both vaccines. No significant<br class=br>increases in the cytokine levels were reported after the 3<sup>rd</sup> dose and;<br class=br><br class=br>&nbsp;&nbsp;&nbsp;Patent parasitemia was detected in all vaccinees upon challenge with<br class=br>sporozoites for all the vaccines.</td><td align=center colspan=1 rowspan=1 valign=top><a name=d9025e1190 class=n-a></a><a href="#ref-18">18</a></td></tr><tr><a name=d9025e1196 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d9025e1198 class=n-a></a><b><i>RTS,S/AS0<sub>1</sub></i> vaccine:</b><br class=br><b>a recombinant</b><br class=br><b>protein based</b><br class=br><b>vaccine</b></td><td align=left colspan=1 rowspan=1 valign=top><a name=d9025e1215 class=n-a></a>&nbsp;&nbsp;&nbsp;PCR-based next generation sequencing of DNA samples<br class=br>obtained from 4,985 study participants was used to analyze<br class=br>circumsporozoite protein polymorphisms;<br class=br><br class=br>&nbsp;&nbsp;&nbsp;Samples representing two protocol-specified end points<br class=br>were sequenced only in participants who received all three<br class=br>vaccinations at months 0, 1, and 2;<br class=br><br class=br>&nbsp;&nbsp;&nbsp;The two protocol endpoints included primary clinical malaria<br class=br>and parasite positivity;<br class=br><br class=br>&nbsp;&nbsp;&nbsp;Samples extracted from study participants were obtained as<br class=br>dried blood spots on Whatman FTA sample cards and;<br class=br><br class=br>&nbsp;&nbsp;&nbsp;The sequencing of circumsporozoite protein C-terminal and<br class=br>SERA-2 amplicons was done on an Illumina MiSeq platform.<br class=br>The sequencing of NANPNVDP amplicon was done on a<br class=br>PacBio platform since it was longer.</td><td align=left colspan=1 rowspan=1 valign=top><a name=d9025e1250 class=n-a></a>&nbsp;&nbsp;&nbsp;Most of the samples obtained from participants with primary clinical<br class=br>malaria in the two age bracket, had complex infections;<br class=br><br class=br>&nbsp;&nbsp;&nbsp;Distribution of complex malaria infection was skewed towards fewer<br class=br>parasite lineages in those who had received <i>RTS,S/AS0<sub>1</sub></i>;<br class=br><br class=br>&nbsp;&nbsp;&nbsp; Among those with high complex malaria, 3D7-matching haplotypes<br class=br>were fewer in those who received <i>RTS,S/AS0<sub>1</sub></i> vaccine compared to<br class=br>those in the control group;<br class=br><br class=br>&nbsp;&nbsp;&nbsp;During the 1<sup>st</sup> year after vaccination, 139 clinical cases of malaria that<br class=br>had a complete full-amplicon 3D7 match and 1951 cases that were<br class=br>mismatched were detected;<br class=br><br class=br>&nbsp;&nbsp;&nbsp;Throughout this time in the category of children aged 717 months the<br class=br>overall efficacy of the vaccine was 50.3% against clinical malaria that<br class=br>had a complete full-amplicon 3D7 match compared to mismatched<br class=br>malaria where the efficacy was 33.4% and;<br class=br><br class=br>&nbsp;&nbsp;&nbsp;In the older age, category the additive vaccine efficacy showed a<br class=br>propensity to reduce as the count of mismatches with 3D7 at these<br class=br>seven amino acid positions reduced.</td><td align=center colspan=1 rowspan=1 valign=top><a name=d9025e1306 class=n-a></a><a href="#ref-16">16</a></td></tr><tr><a name=d9025e1311 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d9025e1313 class=n-a></a><b><i>RTS,S/AS0<sub>1</sub></i> vaccine:</b><br class=br><b>Subunit vaccine</b></td><td align=left colspan=1 rowspan=1 valign=top><a name=d9025e1324 class=n-a></a>&nbsp;&nbsp;&nbsp;Seven year follow-up of participants who had been<br class=br>randomized in two arms with one arm assigned to get<br class=br><i>RTS,S/AS0<sub>1</sub></i> vaccine while the other arm received control<br class=br>(rabies) vaccine;<br class=br><br class=br>&nbsp;&nbsp;&nbsp;The trial was carried out as part of Phase 2 trial of <i>RTS,S/</i><br class=br><i>AS0<sub>1</sub></i> vaccine which was conducted among children that<br class=br>were 517 months of age;<br class=br><br class=br>&nbsp;&nbsp;&nbsp;Double blinded, randomized controlled trial;<br class=br><br class=br> &nbsp;&nbsp;&nbsp;A total of 447 healthy children of ages 517 months in 2007<br class=br>were recruited and followed up for a cumulative duration of<br class=br>seven years;<br class=br><br class=br>&nbsp;&nbsp;&nbsp;The participants were assigned to get either <i>RTS,S/AS0<sub>1</sub></i><br class=br>vaccine or control (rabies vaccine);<br class=br><br class=br>&nbsp;&nbsp;&nbsp;Each subject received a total of three doses; at baseline, 1<br class=br>and 2 months. No other vaccine was administered during<br class=br>the follow up;<br class=br><br class=br>&nbsp;&nbsp;&nbsp;In order to check for cases of asymptomatic parasitemia,<br class=br>blood samples were acquired at 8, 12, 15, 25, 38, 65, 78,<br class=br>and 91 months after vaccination;<br class=br><br class=br>&nbsp;&nbsp;&nbsp;The primary endpoint was presence of clinical malaria as<br class=br>a result of infection with P<i>f</i> and presence of P<i>f</i> in blood at a<br class=br>parasite density of more than 2500/mm<sup>3</sup>;<br class=br><br class=br>&nbsp;&nbsp;&nbsp;Vaccine efficacy was defined as 1 minus the hazard ratio or<br class=br>the incidence-rate ratio multiplied by 100 in the <i>RTS,S/AS0<sub>1</sub></i><br class=br>group versus the control group.</td><td align=left colspan=1 rowspan=1 valign=top><a name=d9025e1415 class=n-a></a>&nbsp;&nbsp;&nbsp;The vaccine effectiveness in preventing the index case of clinical<br class=br>malaria was 27.0% (95% CI, 8.5 to 41.8; P = 0.006). Per protocol<br class=br>analysis yielded comparable results;<br class=br><br class=br>&nbsp;&nbsp;&nbsp;The approximated effectiveness of the vaccine was 4.4% ((95% CI,<br class=br>17.0 to 21.9; P = 0.66). Comparable results were obtained when per<br class=br>protocol analysis was carried out;<br class=br><br class=br>&nbsp;&nbsp;&nbsp;The effectiveness of the trial vaccine appeared to diminish significantly<br class=br>with time. This effect was more pronounced in those participants with<br class=br>high exposure to malaria parasites. The waning effect was also more<br class=br>rapid in the same cohort;<br class=br><br class=br>&nbsp;&nbsp;&nbsp;Conduction of intention to treat analysis yielded a vaccine efficacy of<br class=br>35.9% in the 1<sup>st</sup> year which declined to 3.6% in the 7<sup>th</sup> year of follow<br class=br>up;<br class=br><br class=br>&nbsp;&nbsp;&nbsp;Overall, the cases of clinical malaria that were avoided due to<br class=br>vaccination with <i>RTS,S/AS0<sub>1</sub></i> vaccine throughout the seven year period<br class=br>was 317 cases per 1000 children who received the vaccine;<br class=br><br class=br>&nbsp;&nbsp;&nbsp;Cases averted in the lower exposure group kept on rising throughout<br class=br>the follow up period to a total of 718 cases per 1000 children in the<br class=br>intervention group;<br class=br><br class=br> &nbsp;&nbsp;&nbsp;Both arms had similar percentage of children reporting cases of<br class=br>one or more serious adverse effects and so there was no significant<br class=br>difference between the two;<br class=br><br class=br>&nbsp;&nbsp;&nbsp;15 cases of severe malaria were discovered on follow up (5 in the<br class=br>intervention group and 10 in the control group).</td><td align=center colspan=1 rowspan=1 valign=top><a name=d9025e1487 class=n-a></a><a href="#ref-11">11</a></td></tr><tr><a name=d9025e1492 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d9025e1494 class=n-a></a><b><i>FP9-PP</i> and <i>MVA-</i></b><br class=br><b><i>PP</i>: A recombinant</b><br class=br><b>subunit vaccine.</b></td><td align=left colspan=1 rowspan=1 valign=top><a name=d9025e1510 class=n-a></a>&nbsp;&nbsp;&nbsp;Malaria nave healthy adult volunteers of ages 18 to 50 years<br class=br>from Oxford in UK were enrolled into the study;<br class=br><br class=br>&nbsp;&nbsp;&nbsp;A total of 34 adults were voluntarily included in the study out<br class=br>of whom 15 were enrolled into the single dose escalation<br class=br>cohorts (15) while 19 were included in the prime-boost<br class=br>vaccination cohorts (6 and 7);<br class=br><br class=br>&nbsp;&nbsp;&nbsp;The participants in cohort 6 and 7 were challenged with<br class=br>sporozoites of <i>Plasmodium falciparum</i> 2 weeks after the last<br class=br>vaccine administration;<br class=br><br class=br>&nbsp;&nbsp;&nbsp;Six control participants without vaccination were voluntarily<br class=br>enrolled and underwent malaria challenge with sporozoites<br class=br>of <i>plasmodium falciparum</i>;<br class=br><br class=br>&nbsp;&nbsp;&nbsp;These participants started visiting the clinic on day 6 after<br class=br>the malaria challenge. Specified symptoms associated with<br class=br>malaria and in addition blood samples for thick blood smear<br class=br>and PCR for P<i>f</i> were drawn and;<br class=br><br class=br>&nbsp;&nbsp;&nbsp;Real-time PCR was carried out at the time of sporozoites<br class=br>challenge and during all the subsequent clinic visits until<br class=br>treatment was initiated.</td><td align=left colspan=1 rowspan=1 valign=top><a name=d9025e1567 class=n-a></a>&nbsp;&nbsp;&nbsp;The two vaccines were established to be fairly safe even after<br class=br>escalation of the doses;<br class=br><br class=br>&nbsp;&nbsp;&nbsp;Immunogenicity elicited by single dose vaccines was low. For the<br class=br><i>MVA-PP</i> vaccine, higher doses appeared to yield lower responses at<br class=br>the higher dose of 510<sup>8</sup> pfu;<br class=br><br class=br>&nbsp;&nbsp;&nbsp;In the IFN- ELISPOT assay, the immune response against the P<i>f</i><br class=br>antigens was less than anticipated in comparison with other studies<br class=br>involving different malaria antigens within the same poxvirus vectors;<br class=br><br class=br>&nbsp;&nbsp;&nbsp;All participants enrolled voluntarily and who completed the study<br class=br>(<i>n</i>=21) developed clinical malaria evidenced by positive parasitemia<br class=br>on thick smear and had a positive PCR test for <i>plasmodium</i> malaria;<br class=br><br class=br>&nbsp;&nbsp;&nbsp;The vaccines did not retard the onset of parasitemia in those who<br class=br>received the vaccines compared to the control group;<br class=br><br class=br>&nbsp;&nbsp;&nbsp;Vaccination appeared to marginally slow down blood stage P<i>f</i> growth<br class=br>rate.</td><td align=center colspan=1 rowspan=1 valign=top><a name=d9025e1622 class=n-a></a><a href="#ref-14">14</a></td></tr><tr><a name=d9025e1627 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d9025e1629 class=n-a></a><b><i>ChAd63 MVA</i></b><br class=br><b><i>METRAP:</i> Sub-unit</b><br class=br><b>recombinant vaccine</b></td><td align=left colspan=1 rowspan=1 valign=top><a name=d9025e1642 class=n-a></a>&nbsp;&nbsp;&nbsp;A total of 700 subjects were enrolled. 351 were given 2<br class=br>doses of <i>ME-TRAP</i> while 349 were given 2 doses of the<br class=br>control vaccine;<br class=br><br class=br>&nbsp;&nbsp;&nbsp;Randomized double blind controlled trial;<br class=br><br class=br>&nbsp;&nbsp;&nbsp;Study subjects were aged between 517 months at the time<br class=br>of vaccine vaccination;<br class=br><br class=br>&nbsp;&nbsp;&nbsp;Subjects were randomized in the ratio of 1:1, either to the<br class=br>cohort receiving the <i>ChAd63 ME-TRAP and MVA ME-TRAP</i><br class=br>or the cohort that received the rabies control vaccine;<br class=br><br class=br>&nbsp;&nbsp;&nbsp;The <i>ChAd63 ME-TRAP</i> dose used for purposes of this study<br class=br>was 5  10<sup>10</sup> vp. The amount of MVA ME-TRAP used for<br class=br>purposes of this trial was 1  108 pfu;<br class=br><br class=br>&nbsp;&nbsp;&nbsp;A rabies vaccine called <i>Imovax</i> and administered<br class=br>intramuscularly as a single dose was used for control<br class=br>purposes;<br class=br><br class=br> &nbsp;&nbsp;&nbsp;Assessing for occurrence of solicited adverse events (AE)<br class=br>was done for 7 days after each round of vaccination while<br class=br>unsolicited AEs were monitored up to a period of 1 month<br class=br>after vaccination for both study and control subjects. Close<br class=br>observation for serious adverse events happened through<br class=br>the study period;<br class=br><br class=br>&nbsp;&nbsp;&nbsp;Existence of neutralizing Abs against <i>ChAd63</i> was not a<br class=br>basis of selection of subjects;<br class=br><br class=br>&nbsp;&nbsp;&nbsp;Existence of a blood related, renal or any chronic illness and<br class=br>prior receipt of malaria investigative drugs of vaccine by the<br class=br>target subjects served as a basis of exclusion from study;<br class=br><br class=br>&nbsp;&nbsp;&nbsp;Laboratory assays for T-cell responses to <i>ME-TRAP</i> was<br class=br>performed on IFN- ELISPOT while; assaying for <i>TRAP</i><br class=br>specific IgG Abs was performed on ELISA. </td><td align=left colspan=1 rowspan=1 valign=top><a name=d9025e1738 class=n-a></a>&nbsp;&nbsp;&nbsp;There was notable higher local pain among the vaccine cohorts<br class=br>(15.4%) as compared to the control cohort (0.3%). Other solicited<br class=br>events include: drowsiness, low appetite and fever. The most severe<br class=br>AEs included pneumonia, non-severe malaria, GIT irritation and<br class=br>undernourishment especially to the vaccine cohort than the control<br class=br>cohort;<br class=br><br class=br>&nbsp;&nbsp;&nbsp;There were four deaths during the trail, 1 from the <i>ME-TRAP</i> (80<sup>th</sup> day<br class=br>after vaccination) cohort while 3 from rabies control vaccine cohort.<br class=br>None of the cases was associated with the study vaccines;<br class=br><br class=br>&nbsp;&nbsp;&nbsp;IFN- Ag specific T-cells escalated among subjects who were<br class=br>vaccinated with <i>ChAd63 MVA ME-TRAP</i>;<br class=br><br class=br>&nbsp;&nbsp;&nbsp;At baseline, 2 out of 169 subjects had anti-<i>TRAP</i> IgG Abs; 122 of 169<br class=br>had anti-<i>TRAP</i> IgG Abs after priming and 165 out of 169 had anti-<br class=br><i>TRAP</i> after boosting;<br class=br><br class=br>&nbsp;&nbsp;&nbsp;A total of 424 subjects had clinical malaria qualifying the primary case<br class=br>definition during the study period.</td><td align=center colspan=1 rowspan=1 valign=top><a name=d9025e1795 class=n-a></a><a href="#ref-13">13</a></td></tr><tr><a name=d9025e1800 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d9025e1802 class=n-a></a><b><i>RTS,S/AS0<sub>1</sub></i>: A</b><br class=br><b>subunit vaccine</b></td><td align=left colspan=1 rowspan=1 valign=top><a name=d9025e1813 class=n-a></a>&nbsp;&nbsp;&nbsp;The design was randomized, double blind phase III trial;<br class=br><br class=br>&nbsp;&nbsp;&nbsp;Healthy subjects aged between 517 months at the time of<br class=br>1<sup>st</sup> vaccination were eligible for the study;<br class=br><br class=br>&nbsp;&nbsp;&nbsp;Vaccination with 3 doses of Hepatitis B vaccines was a<br class=br>requirement for inclusion;<br class=br><br class=br>&nbsp;&nbsp;&nbsp;A total of 320 subjects were randomized in the ratio of<br class=br>1:1:1:1 (80 subjects/group) in order to receive 1 of 3 lots<br class=br>or the comparator lot of <i>RTS,S/AS0<sub>1</sub></i> following a 0,1 and 2<br class=br>months schedule;<br class=br><br class=br>&nbsp;&nbsp;&nbsp;Anti-circumsporozoite Abs (Anti-CS Abs) (IgG) were<br class=br>measured on ELISA before administration of the 1<sup>st</sup> dose<br class=br>and 1 month after completion of the 3<sup>rd</sup> dose;<br class=br><br class=br>&nbsp;&nbsp;&nbsp;Solicited local and general AEs (redness, swelling and pain<br class=br>at injection site and; drowsiness, fever and loss of appetite),<br class=br>unsolicited AEs and serious AEs were trailed for 7 days, 30<br class=br>days and through the study period respectively.</td><td align=left colspan=1 rowspan=1 valign=top><a name=d9025e1868 class=n-a></a>&nbsp;&nbsp;&nbsp;Anti-CS IgG GMT ratio was between 0.5 to 2 one month after<br class=br>completion of the 3<sup>rd</sup> dose;<br class=br><br class=br>&nbsp;&nbsp;&nbsp;The GMT for anti-CS was 271.7EU/ml and 285.8EU/ml for the pilot and<br class=br>commercial lots respectively;<br class=br><br class=br>&nbsp;&nbsp;&nbsp;Anti-CS prevalence was 3% before vaccination and levels escalated to<br class=br>seropositivity 1 month after completing the last dose of vaccine across<br class=br>all cohorts;<br class=br><br class=br>&nbsp;&nbsp;&nbsp;Most subjects (91.8%) in each cohort had anti-HBs Abs before<br class=br>vaccination;<br class=br><br class=br>&nbsp;&nbsp;&nbsp;Pain and fever were the most prevalent solicited local and general AEs<br class=br>reported and; 13 unsolicited severe AEs were also reported.</td><td align=center colspan=1 rowspan=1 valign=top><a name=d9025e1900 class=n-a></a><a href="#ref-19">19</a></td></tr></tbody></table></div></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d9025e1911>Discussion</h2><p class="" id=d9025e1914>The <i>RTS,S</i> vaccine is by far the most advanced malaria vaccine in clinical development today. The vaccine confers its protective effect by targeting the circumsporozoite protein (CSP), a specific protein expressed by parasites in the pre-erythrocytic stage of the <i>Plasmodium falciparum</i> (Pf) human life cycle<sup><a href="#ref-8">8</a></sup>. In specific field trials, <i>RTS,S</i>-containing vaccines have been administered with either the <i>AS01</i> or <i>AS02</i> adjuvant systems<sup><a href="#ref-8">8</a></sup>. By virtue of their intrinsic properties and composition, therefore, vaccines containing the <i>RTS,S</i> formulation impart partial pre-erythrocytic immunity which is distinct from naturally-acquired immunity that mainly targets blood-stage parasites<sup><a href="#ref-8">8</a>,<a href="#ref-16">16</a></sup>. The latter type of immunity is hypothesized to be mediated mainly by T- and B-cell responses, as well as other possible mechanisms that are not presently well defined. An immuno-epidemiological study conducted by Bejon <i>et al</i> in 2011 concluded that vaccination of young children with the <i>RTS,S/AS01E</i> vaccine resulted in reduced exposure to blood-stage parasites, therefore reducing anti-merozoite antigen antibody concentrations. The antibodies were, however, not correlates of clinical immunity to malaria<sup><a href="#ref-8">8</a></sup>. This is a serious concern associated with use of the <i>RTS,S</i> vaccine in the general population.</p><p class="" id=d9025e1965>Several attempts have been made to improve the protective efficacy of the <i>RTS,S</i> vaccines. These include, but are not limited to, formulation with more potent adjuvant systems, use of boosted regimens with other CSP-expressing regimens and evaluation of other Pf antigens separately or in combination with <i>RTS,S</i>. An example of such a study was conducted using RTS,S combined with a recombinant form of thrombospondin related anonymous protein (<i>TRAP</i>) of Pf (<i>PfTRAP</i>)<sup><a href="#ref-18">18</a></sup>. Measurement of antigen-specific antibody responses, lymphoproliferative responses and IFN production due to the combination vaccine were similar to those produced by each of the single component vaccines. However, both the phase 1 and 2 clinical studies conducted by the investigators indicated inferior protective efficacy with the <i>RTS,S/TRAP</i> combination compared to single <i>RTS,S/AS02</i> vaccine<sup><a href="#ref-18">18</a></sup>. This was attributed to possible immunological interference, a phenomenon whereby multiple antigens interfere with T-cell priming and restimulation expected with a single antigen. The study was also limited by its significantly small sample size. Future combinations should perform preliminary exclusion of possible immunological interference between component antigens to improve success rates of such boosted regimens.</p><p class="" id=d9025e1995>An important consideration about use of the <i>RTS,S</i> vaccines is their duration of protective effect in the general population. Field trials of the vaccine have been conducted on infants and young children, where the vaccine has demonstrated average protection rates of between 1836% with 34 doses of the vaccine administered during a 48-month follow-up period<sup><a href="#ref-11">11</a></sup>. These trials were conducted in different African sites with varying rates of malaria transmission. Follow-up studies spanning a period of seven years however produced disappointing results on the long-term protective efficacy of the <i>RTS,S</i> malaria vaccine. From the two clinical studies, it was concluded that a three-dose vaccination regimen with <i>RTS,S/AS01</i> vaccine offered initial protection against clinical malaria. The result was however offset in subsequent years, especially in areas with higher-than-average exposure to the parasites. Also, anti-merozoite antibody levels in vaccinated individuals were poor correlates of clinical immunity<sup><a href="#ref-11">11</a></sup>.</p><p class="" id=d9025e2015>A recent study investigating the relationship between protective efficacy of the <i>RTS,S/AS01</i> malaria vaccine and CSP polymorphisms in localized parasite population genotypes indicated that protective efficacy of the vaccine was higher in malaria parasites with matched CSP alleles than those with unmatched alleles<sup><a href="#ref-16">16</a></sup>. This finding is important because CSP polymorphisms and differences in haplotypic regions of the protein exert an effect of vaccine efficacy<sup><a href="#ref-16">16</a></sup>. Significant differences were observed in the cumulative vaccine efficiency rate between different age groups, based on the CSP polymorphisms. Therefore, it may be helpful to incorporate CSP polymorphisms in the local parasite population in future vaccine development efforts. Such an expensive venture would definitely impact on the cost of production, and availability, of these tailor-made malaria vaccines.</p><p class="" id=d9025e2030>On the bright side, a study investigating the immunogenicity and safety of commercially produced <i>RTS,S/AS01</i> malaria vaccine on a lot-to-lot basis yielded encouraging results. No significant variations were noted between the <i>RTS,S/AS01</i> vaccine lots formulated from a commercial-scale purified antigen bulk batch compared to those formulated from a pilot-scale antigen bulk batch<sup><a href="#ref-19">19</a></sup>. This is an encouraging prospect for future production of multiple batches of the <i>RTS,S</i> pre-erythrocytic vaccines especially in resource-limited settings which are also malaria endemic.</p><p class="" id=d9025e2046>A different approach from the <i>RTS,S</i> vaccine adopted in the last decade has led to development of the Pf sporozoite (<i>PfSPZ</i>) vaccine<sup><a href="#ref-12">12</a></sup>. This vaccine contains radiation-attenuated sporozoites of the parasite, and was assessed for tolerability, safety, immunogenicity and protective efficacy. The <i>PfSPZ</i> vaccine was administered by direct venous inoculation of 35 doses in non-immune individuals<sup><a href="#ref-12">12</a></sup>. The <i>PfSPZ</i> vaccine, given in a three-dose regimen, protected against both 3- and 24-week homologous (similar strain as in vaccine) controlled malaria infections. No significantly alarming side effects were associated with the trialed regimens of this vaccine, and this is an encouraging outcome for future applications of the <i>PfSPZ</i> vaccine in mass malaria vaccination campaigns. Upcoming phase III trials of the vaccine will provide further insights on the protective efficacy and safety of the vaccine, especially against heterologous (different strain from vaccine) infections.</p><p class="" id=d9025e2073>Furthermore, a polyprotein (PP) pre-erythrocytic malaria vaccine containing the entire sequence of six separate <i>Pf</i> proteins has been investigated. This vaccine was delivered using the combined viral vectors fowl pox virus strain FP9 and modified vaccinia virus Ankara (<i>MVA</i>)<sup><a href="#ref-14">14</a></sup>. The design strategy of this polyprotein vaccine was targeted at producing a broad antibody response against a broad range of plasmodial pre-erythrocytic antigens, as opposed to a strong but narrow response. No serious adverse effects were observed with both the <i>FP9-PP</i> and <i>MVA-PP</i> vaccines, but both failed to induce protection against sporozoite challenge or delay onset of parasitemia in vaccinated individuals<sup><a href="#ref-14">14</a></sup>. The investigators attributed this outcome to possible limits in the size of immunogenic pre-erythrocytic proteins, at least when attached to viral vectors. Future work in the design of PP pre-erythrocytic malaria vaccines should therefore attempt to investigate the theory of size limits to immunogenicity, as well as effects of specific combinations and sizes to efficiency of the viral vectors employed. In addition, a separate phase IIa study utilizing the chimpanzee adenovirus 63 (<i>ChAd63</i>) and MVA vectors to express a <i>TRAP</i>-based vaccine yielded more promising results<sup><a href="#ref-13">13</a></sup>. Both vaccines were demonstrated to be safe and adequately immunogenic, but induced only moderate T-cell response. This immunogenic response was not sufficient to provide protection against clinical malaria in the follow-up period. Despite these results, viral vectors have a role in malaria vaccine delivery and future work should further investigate novel viral vectors as well as increased applicability in design of pre-erythrocytic vaccines.</p><p class="" id=d9025e2107>Although CSP has stood out over the last few years as an immuno-dominant pre-erythrocytic antigen, several other proteins can be utilized in the design of pre-erythrocytic malaria vaccines. A study of 27 different pre-erythrocytic antigens indicated that 21 out of those, all localized to different parts of the sporozoite, induced detectable antibody responses in animal models<sup><a href="#ref-9">9</a></sup>. These antigens elicited adequate antibody and T-cell responses and are therefore possible vaccine candidates. In future development of pre-erythrocytic malaria vaccines, thorough investigation of these additional sporozoite proteins should be undertaken to explore their viability as starting points for vaccine development. It would be interesting to explore these additional proteins as vaccine candidates.</p><p class="" id=d9025e2114>This review had some limitations. We only considered vaccine candidates in clinical trials in the past decade. Therefore, promising vaccine candidates which have not yet been approved for clinical trials were not considered. In addition, only the vaccine candidates affecting the pre-erythrocytic stage were evaluated yet it is possible for a molecule affecting the erythrocytic stage to be an effective malaria vaccine. Articles published in another language apart from English were not included leading to exemption of potentially promising vaccine candidates.</p></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d9025e2120>Conclusion</h2><p class="" id=d9025e2123>The search for a malaria vaccine targeting the pre-erythrocytic stage of the Pf has led to development of sub-unit vaccines, for example, <i>RTS,S</i> vaccine &amp; <i>ChAd63 MVA METRAP</i> vaccine and inactivated vaccines like radiation attenuated Pf sporozoite vaccine. However, these vaccines have not been shown to induce sufficient immune responses required to provide adequate protection against malaria. The <i>RTS,S</i> vaccine currently undergoing clinical trials remains the most promising. However, its inability to confer long-term protection against clinical malaria and the varied antibody responses associated with the vaccine remain major drawbacks. The attenuated sporozoite vaccine is also a promising option, and ongoing clinical trials are vital in providing conclusions on the protective effect of this vaccine. Most importantly, ability of the <i>PfSPZ</i> vaccine to impart protection against heterologous malaria infections will be vital. Use of viral vectors for malaria vaccines has proven to be a viable mode of delivery. Further work is needed to identify optimal viral vectors for maximum protective efficacy. In addition, the possibility of using combined antigens in a single vaccine and further exploration of other plasmodial antigens as vaccine candidates are both routes that need to be pursued.</p></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d9025e2142>Data availability</h2><div class=section><a name=d9025e2145 class=n-a></a><h3 class=section-title>Underlying data</h3><p class="" id=d9025e2150>All data underlying the results are available as part of the article and no additional source data are required.</p></div><div class=section><a name=d9025e2154 class=n-a></a><h3 class=section-title>Reporting guidelines</h3><p class="" id=d9025e2159>Harvard Dataverse: PRISMA-ScR checklist for Malaria vaccines targeting the pre-erythrocytic stage: a systematic review, <a target=xrefwindow href="https://doi.org/10.7910/DVN/ZK3ZZH" id=d9025e2161>https://doi.org/10.7910/DVN/ZK3ZZH</a><sup><a href="#ref-20">20</a></sup>.</p></div></div><div id=article1-back class=generated-article-footer><div class=back-section><a name=d9025e2173 class=n-a></a><h2 class=main-title id=d9025e2175>Acknowledgements</h2><p class="" id=d9025e2178>We acknowledge the technical input of Ms. Regina Njeru of the International Livestock Research Institute (ILRI). We are very grateful that she made time to give her valuable contribution.</p></div><div class=back-section><a name=d9025e2182 class=n-a></a><span class="research-layout prime-recommended-wrapper reference-heading is-hidden"><span class=faculty-opinion-icon></span><span class="prime-red big">Faculty Opinions recommended</span></span><h2 class=main-title id=d9195>References</h2><div class="section ref-list"><a name=d9025e2182 class=n-a></a><ul><li><a name=ref-1 class=n-a></a><span class=label>1. </span>&nbsp;<span class=citation><a name=d9025e2189 class=n-a></a>World Health Organization World Malaria Report: World Health. WHO/HTM/GM, 2010; <b>238</b>. <a target=xrefwindow id=d9025e2194 href="https://www.google.com/search?client=firefox-b-d&amp;q=World+Health">Reference Source</a></span></li><li><a name=ref-2 class=n-a></a><span class=label>2. </span>&nbsp;<span class=citation><a name=d9025e2203 class=n-a></a>Sultana M, Sheikh N, Mahumud RA, <i> et al.</i>: Prevalence and associated determinants of malaria parasites among Kenyan children. <i>Trop Med Health.</i> 2017; <b>45</b>: 25. <a target=xrefwindow id=d9025e2214 href="http://www.ncbi.nlm.nih.gov/pubmed/29085254">PubMed Abstract </a> | <a target=xrefwindow id=d9025e2217 href="https://doi.org/10.1186/s41182-017-0066-5">Publisher Full Text </a> | <a target=xrefwindow id=d9025e2221 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5651573">Free Full Text </a></span></li><li><a name=ref-3 class=n-a></a><span class=label>3. </span>&nbsp;<span class=citation><a name=d9025e2230 class=n-a></a>Halliday KE, Okello G, Turner EL, <i> et al.</i>: Impact of Intermittent Screening and Treatment for Malaria among School Children in Kenya: A Cluster Randomised Trial. <i>PLoS Med.</i> 2014; <b>11</b>(1): e1001594. <a target=xrefwindow id=d9025e2241 href="http://www.ncbi.nlm.nih.gov/pubmed/24492859">PubMed Abstract </a> | <a target=xrefwindow id=d9025e2244 href="https://doi.org/10.1371/journal.pmed.1001594">Publisher Full Text </a> | <a target=xrefwindow id=d9025e2248 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3904819">Free Full Text </a></span></li><li><a name=ref-4 class=n-a></a><span class=label>4. </span>&nbsp;<span class=citation><a name=d9025e2257 class=n-a></a>West PA, Protopopoff N, Wright A, <i> et al.</i>: Indoor Residual Spraying in Combination with Insecticide-Treated Nets Compared to Insecticide-Treated Nets Alone for Protection against Malaria: A Cluster Randomised Trial in Tanzania. <i>PLoS Med.</i> 2014; <b>11</b>(4): e1001630. <a target=xrefwindow id=d9025e2268 href="http://www.ncbi.nlm.nih.gov/pubmed/24736370">PubMed Abstract </a> | <a target=xrefwindow id=d9025e2271 href="https://doi.org/10.1371/journal.pmed.1001630">Publisher Full Text </a> | <a target=xrefwindow id=d9025e2275 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3988001">Free Full Text </a></span></li><li><a name=ref-5 class=n-a></a><span class=label>5. </span>&nbsp;<span class=citation><a name=d9025e2284 class=n-a></a>Coelho CH, Doritchamou JYA, Zaidi I, <i> et al.</i>: Advances in malaria vaccine development: Report from the 2017 malaria vaccine symposium. <i>npj Vaccines.</i> 2017; <b>2</b>: 34. <a target=xrefwindow id=d9025e2295 href="http://www.ncbi.nlm.nih.gov/pubmed/29522056">PubMed Abstract </a> | <a target=xrefwindow id=d9025e2298 href="https://doi.org/10.1038/s41541-017-0035-3">Publisher Full Text </a> | <a target=xrefwindow id=d9025e2302 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5709382">Free Full Text </a></span></li><li><a name=ref-6 class=n-a></a><span class=label>6. </span>&nbsp;<span class=citation><a name=d9025e2312 class=n-a></a>Crompton PD, Pierce SK, Miller LH: Advances and challenges in malaria vaccine development. <i>J Clin Invest.</i> 2010; <b>120</b>(12): 416878. <a target=xrefwindow id=d9025e2320 href="http://www.ncbi.nlm.nih.gov/pubmed/21123952">PubMed Abstract </a> | <a target=xrefwindow id=d9025e2323 href="https://doi.org/10.1172/JCI44423">Publisher Full Text </a> | <a target=xrefwindow id=d9025e2326 href="http://www.ncbi.nlm.nih.gov/pmc/articles/2994342">Free Full Text </a></span></li><li><a name=ref-7 class=n-a></a><span class=label>7. </span>&nbsp;<span class=citation><a name=d9025e2335 class=n-a></a>Duffy PE, Sahu T, Akue A, <i> et al.</i>: Pre-erythrocytic malaria vaccines: identifying the targets. <i>Expert Rev Vaccines.</i> 2012; <b>11</b>(10): 126180. <a target=xrefwindow id=d9025e2346 href="http://www.ncbi.nlm.nih.gov/pubmed/23176657">PubMed Abstract </a> | <a target=xrefwindow id=d9025e2349 href="https://doi.org/10.1586/erv.12.92">Publisher Full Text </a> | <a target=xrefwindow id=d9025e2353 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3584156">Free Full Text </a></span></li><li><a name=ref-8 class=n-a></a><span class=label>8. </span>&nbsp;<span class=citation><a name=d9025e2362 class=n-a></a>Bejon P, Cook J, Bergmann-Leitner E, <i> et al.</i>: Effect of the pre-erythrocytic candidate malaria vaccine RTS,S/AS01E on blood stage immunity in young children. <i>J Infect Dis.</i> 2011; <b>204</b>(1): 918. <a target=xrefwindow id=d9025e2373 href="http://www.ncbi.nlm.nih.gov/pubmed/21628653">PubMed Abstract </a> | <a target=xrefwindow id=d9025e2376 href="https://doi.org/10.1093/infdis/jir222">Publisher Full Text </a> | <a target=xrefwindow id=d9025e2380 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3105039">Free Full Text </a></span></li><li><a name=ref-9 class=n-a></a><span class=label>9. </span>&nbsp;<span class=citation><a name=d9025e2389 class=n-a></a>Aguiar JC, Bolton J, Wanga J, <i> et al.</i>: Discovery of novel plasmodium falciparum pre-erythrocytic antigens for vaccine development. <i>PLoS One.</i> 2015; <b>10</b>(8): e0136109. <a target=xrefwindow id=d9025e2400 href="http://www.ncbi.nlm.nih.gov/pubmed/26292257">PubMed Abstract </a> | <a target=xrefwindow id=d9025e2403 href="https://doi.org/10.1371/journal.pone.0136109">Publisher Full Text </a> | <a target=xrefwindow id=d9025e2407 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4546230">Free Full Text </a></span></li><li><a name=ref-10 class=n-a></a><span class=label>10. </span>&nbsp;<span class=citation><a name=d9025e2416 class=n-a></a>Ndungu FM, Mwacharo J, Wambua J, <i> et al.</i>: A seven-year study on the effect of the pre-erythrocytic malaria vaccine candidate RTS,S/AS01<sub>E</sub> on blood stage immunity in young kenyan children [version 1; peer review: 1 approved, 2 approved with reservations]. <i>Wellcome Open Res.</i> 2019; <b>4</b>: 42. <a target=xrefwindow id=d9025e2430 href="http://www.ncbi.nlm.nih.gov/pubmed/31168483">PubMed Abstract </a> | <a target=xrefwindow id=d9025e2434 href="https://doi.org/10.12688/wellcomeopenres.15002.1">Publisher Full Text </a> | <a target=xrefwindow id=d9025e2437 href="http://www.ncbi.nlm.nih.gov/pmc/articles/6545824">Free Full Text </a></span></li><li><a name=ref-11 class=n-a></a><span class=label>11. </span>&nbsp;<span class=citation><a name=d9025e2446 class=n-a></a>Olotu A, Fegan G, Wambua J: Seven-Year Efficacy of RTS,S/AS01 Malaria Vaccine Among Young African Children <i>N Engl J Med.</i> 2016; <b>374</b>(26): 251929. <a target=xrefwindow id=d9025e2454 href="http://www.ncbi.nlm.nih.gov/pubmed/27355532">PubMed Abstract </a> | <a target=xrefwindow id=d9025e2457 href="https://doi.org/10.1056/NEJMoa1515257">Publisher Full Text </a> | <a target=xrefwindow id=d9025e2460 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4962898">Free Full Text </a></span></li><li><a name=ref-12 class=n-a></a><span class=label>12. </span>&nbsp;<span class=citation><a name=d9025e2470 class=n-a></a>Epstein JE, Paolino KM, Richie TL, <i> et al.</i>: Protection against <i>Plasmodium falciparum</i> malaria by PfSPZ Vaccine. <i>JCI Insight.</i> 2017; <b>2</b>(1): 114. <a target=xrefwindow id=d9025e2484 href="http://www.ncbi.nlm.nih.gov/pubmed/28097230">PubMed Abstract </a> | <a target=xrefwindow id=d9025e2488 href="https://doi.org/10.1172/jci.insight.89154">Publisher Full Text </a> | <a target=xrefwindow id=d9025e2491 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5214067">Free Full Text </a></span></li><li><a name=ref-13 class=n-a></a><span class=label>13. </span>&nbsp;<span class=citation><a name=d9025e2500 class=n-a></a>Tiono AB, Nbi I, Anagnostou N, <i> et al.</i>: First field efficacy trial of the ChAd63 MVA ME-TRAP vectored malaria vaccine candidate in 5-17 months old infants and children. <i>PLoS One.</i> 2018; <b>13</b>(12): e0208328. <a target=xrefwindow id=d9025e2511 href="http://www.ncbi.nlm.nih.gov/pubmed/30540808">PubMed Abstract </a> | <a target=xrefwindow id=d9025e2514 href="https://doi.org/10.1371/journal.pone.0208328">Publisher Full Text </a> | <a target=xrefwindow id=d9025e2518 href="http://www.ncbi.nlm.nih.gov/pmc/articles/6291132">Free Full Text </a></span></li><li><a name=ref-14 class=n-a></a><span class=label>14. </span>&nbsp;<span class=citation><a name=d9025e2527 class=n-a></a>Porter DW, Thompson FM, Berthoud TK, <i> et al.</i>: A human phase I/IIa malaria challenge trial of a polyprotein malaria vaccine. <i>Vaccine.</i> 2011; <b>29</b>(43): 751422. <a target=xrefwindow id=d9025e2538 href="http://www.ncbi.nlm.nih.gov/pubmed/21501642">PubMed Abstract </a> | <a target=xrefwindow id=d9025e2541 href="https://doi.org/10.1016/j.vaccine.2011.03.083">Publisher Full Text </a> | <a target=xrefwindow id=d9025e2545 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3195259">Free Full Text </a></span></li><li><a name=ref-15 class=n-a></a><span class=label>15. </span>&nbsp;<span class=citation><a name=d9025e2554 class=n-a></a>Shamseer L, Moher D, Clarke M, <i> et al.</i>: Preferred reporting items for systematic review and meta-analysis protocols (prisma-p) 2015: Elaboration and explanation. <i>BMJ.</i> 2015; <b>350</b>: g7647. <a target=xrefwindow id=d9025e2565 href="http://www.ncbi.nlm.nih.gov/pubmed/25555855">PubMed Abstract </a> | <a target=xrefwindow id=d9025e2568 href="https://doi.org/10.1136/bmj.g7647">Publisher Full Text </a></span></li><li><a name=ref-16 class=n-a></a><span class=label>16. </span>&nbsp;<span class=citation><a name=d9025e2577 class=n-a></a>Neafsey DE, Juraska M, Bedford T, <i> et al.</i>: Genetic diversity and protective efficacy of the RTS,S/AS01 malaria vaccine. <i>N Engl J Med.</i> 2015; <b>373</b>: 20252037. <a target=xrefwindow id=d9025e2588 href="https://doi.org/10.1056/NEJMoa1505819">Publisher Full Text </a></span></li><li><a name=ref-17 class=n-a></a><span class=label>17. </span>&nbsp;<span class=citation><a name=d9025e2597 class=n-a></a>Agnandji ST, Lell B, Soulanoudjingar SS, <i> et al.</i>: First results of phase 3 trial of RTS,S/AS01 malaria vaccine in African children. <i>N Engl J Med.</i> 2011; <b>365</b>(20): 18631875. <a target=xrefwindow id=d9025e2608 href="http://www.ncbi.nlm.nih.gov/pubmed/22007715">PubMed Abstract </a> | <a target=xrefwindow id=d9025e2611 href="https://doi.org/10.1056/NEJMoa1102287">Publisher Full Text </a></span></li><li><a name=ref-18 class=n-a></a><span class=label>18. </span>&nbsp;<span class=citation><a name=d9025e2621 class=n-a></a>Kester KE, Gray Heppner D, Moris P, <i> et al.</i>: Sequential Phase 1 and Phase 2 randomized, controlled trials of the safety, immunogenicity and efficacy of combined pre-erythrocytic vaccine antigens RTS,S and TRAP formulated with AS02 Adjuvant System in healthy, malaria nave adults. <i>Vaccine.</i> 2014; <b>32</b>(49): 66836691. <a target=xrefwindow id=d9025e2632 href="http://www.ncbi.nlm.nih.gov/pubmed/24950358">PubMed Abstract </a> | <a target=xrefwindow id=d9025e2635 href="https://doi.org/10.1016/j.vaccine.2014.06.033">Publisher Full Text </a></span></li><li><a name=ref-19 class=n-a></a><span class=label>19. </span>&nbsp;<span class=citation><a name=d9025e2644 class=n-a></a>Umeh R, Oguche S, Oguonu T, <i> et al.</i>: Immunogenicity and safety of the candidate RTS,S/AS01 vaccine in young Nigerian children: A randomized, double-blind, lot-to-lot consistency trial. <i>Vaccine.</i> 2014; <b>32</b>(48): 65566562. <a target=xrefwindow id=d9025e2655 href="http://www.ncbi.nlm.nih.gov/pubmed/25077418">PubMed Abstract </a> | |<a target=xrefwindow id=d9025e2658 href="https://doi.org/10.1016/j.vaccine.2014.07.067">Publisher Full Text </a></span></li><li><a name=ref-20 class=n-a></a><span class=label>20. </span>&nbsp;<span class=citation><a name=d9025e2667 class=n-a></a>Walekhwa M: Malaria vaccines targeting the pre-erythrocytic stage: a systematic review. <i>Harvard Dataverse, V3.</i>2020. <a target=xrefwindow id=d9025e2672 href="https://dataverse.harvard.edu/dataset.xhtml?persistentId=doi:10.7910/DVN/ZK3ZZH">Reference Source</a></span></li></ul></div></div></div> </div> <div class=f1r-article-desk> <section class="o-box o-box--medium u-bg--2 u-mt--2"> <h4 class="u-mt--0 u-mb--2 t-h3 u-weight--md">Looking for the Open Peer Review Reports?</h4> <p class="u-mt--0 u-mb--0 t-h4">They can now be found at the top of the panel on the right, linked from the box entitled Open Peer Review. Choose the reviewer report you wish to read and click the 'read' link. You can also read all the peer review reports by <a target=_blank href="https://f1000research.com/articles/9-680/v1/pdf?article_uuid=42c4b4ec-2cad-4876-a4ea-1277540a9d7e">downloading the PDF</a>.</p> </section> </div> <div id=article-comments class="article-comments padding-bottom-20"> <div class=current-article-comment-section> <h2 class=main-title name=add-new-comment id=add-new-comment> <span class="research-layout f1r-article-mobile-inline valign-middle"> <span class="f1r-icon icon-104_comments size30"></span> </span> <span class=f1r-article-desk-inline>Comments on this article</span> <span class=f1r-article-mobile-inline>Comments (0)</span> <span class="f1r-article-mobile-inline float-right"> <span class="f1r-icon icon-14_more_small"></span> <span class="f1r-icon icon-10_less_small"></span> </span> </h2> </div> <div class="f1r-article-desk-inline referee-report-info-box referee-report-version-box"> Version 1 </div> <div class="f1r-article-mobile research-layout mobile-version-info padding-top-30"> <span class=mversion>VERSION 1</span> <span class=details>PUBLISHED 07 Jul 2020</span> <span class="article-pubinfo-mobile versions-section"> </span> </div> <div class="f1r-article-mobile research-layout margin-top-20 is-centered"> <a href="/login?originalPath=/articles/9-680.html&scrollTo=add-new-comment" class=register-report-comment-button data-test-id=add-comment_mob> <button class="primary orange extra-padding comment-on-this-report">ADD YOUR COMMENT</button> </a> </div> <a href="/login?originalPath=/articles/9-680.html&scrollTo=add-new-comment" class="f1r-article-desk register-report-comment-button" data-test-id=add-comment> <span class=contracted></span>Comment </a> </div> <div class="f1r-article-mobile margin-bottom-30"> <div class=contracted-details> <a href="#" class="contracted-details-label author-affiliations"><span class=contracted></span>Author details</a> <a href="#" class=section-title>Author details</a> <span class="f1r-icon icon-14_more_small section-control"></span> <span class="f1r-icon icon-10_less_small section-control"></span> <div class="expanded-details affiliations is-hidden"> <sup>1</sup> Department of Biomedical Sciences, Kabarak University, Nakuru, Kenya, 20157, Kenya<br/> <sup>2</sup> Department of Pharmaceutical Chemistry &amp; Pharmaceutics, Kabarak University, Nakuru, Kenya, 20157, Kenya<br/> <sup>3</sup> Department of Pre-Clinical, Kabarak University, Nakuru, Kenya, 20157, Kenya<br/> <sup>4</sup> Pharmacology &amp; Pharmacognosy, Kabarak University, Nakuru, Kenya, 20157, Kenya<br/> <sup>5</sup> Department of Physical &amp; Biological Sciences, Kabarak University, Nakuru, Kenya, 20157, Kenya<br/> <sup>6</sup> Department of Pharmacy, Nakuru Level V Hospital, Nakuru, Kenya, 20157, Kenya<br/> <p> <div class=margin-bottom> Teresa Ogeto <br/> <span>Roles: </span> Methodology, Writing  Original Draft Preparation </div> <div class=margin-bottom> Ferdinand Ndubi <br/> <span>Roles: </span> Conceptualization, Writing  Original Draft Preparation </div> <div class=margin-bottom> Mary Murithi <br/> <span>Roles: </span> Conceptualization, Methodology, Writing  Original Draft Preparation </div> <div class=margin-bottom> Richard Kagia <br/> <span>Roles: </span> Conceptualization, Writing  Original Draft Preparation </div> <div class=margin-bottom> Esbon Wambugu <br/> <span>Roles: </span> Formal Analysis, Writing  Original Draft Preparation </div> <div class=margin-bottom> Titus Suge <br/> <span>Roles: </span> Resources, Writing  Review & Editing </div> <div class=margin-bottom> Carolyne Chepkirui <br/> <span>Roles: </span> Conceptualization, Writing  Review & Editing </div> <div class=margin-bottom> Josephat Tonui <br/> <span>Roles: </span> Conceptualization, Formal Analysis, Writing  Original Draft Preparation </div> <div class=margin-bottom> Fiona Maiyo <br/> <span>Roles: </span> Formal Analysis, Methodology, Writing  Review & Editing </div> <div class=margin-bottom> Lydia Momanyi <br/> <span>Roles: </span> Conceptualization, Resources, Writing  Review & Editing </div> <div class=margin-bottom> Michael Walekhwa <br/> <span>Roles: </span> Conceptualization, Project Administration, Writing  Original Draft Preparation, Writing  Review & Editing </div> </p> </div> </div> <div class=contracted-details> <a href="#" class=section-title>Article Versions (1)</a> <span class="f1r-icon icon-14_more_small section-control"></span> <span class="f1r-icon icon-10_less_small section-control"></span> <div class="expanded-details grant-information article-page is-hidden"> <div> <a href="https://f1000research.com/articles/9-680/v1" title="Open version 1 of this article." class="" gahelper=1>version 1</a> <span class="article-pubinfo-mobile versions-section"> </span> </div> <div> Published: 07 Jul 2020, 9:680 </div> <div class=""><a href="https://doi.org/10.12688/f1000research.24320.1">https://doi.org/10.12688/f1000research.24320.1</a></div> </div> </div> <div class=contracted-details> <a href="#" class=section-title> <span class="f1r-icon icon-100_open_access"></span> Copyright </a> <span class="f1r-icon icon-14_more_small section-control"></span> <span class="f1r-icon icon-10_less_small section-control"></span> <div class="expanded-details grant-information article-page is-hidden">  2020 Ogeto T <em>et al</em>. This is an open access article distributed under the terms of the <a href="http://creativecommons.org/licenses/by/4.0/" target=_blank data-test-id=box-licence-link>Creative Commons Attribution License</a>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. </div> </div> <div class="padding-top-30 research-layout"> <div class=article-toolbox-wrapper-mobile> <div class=article-tools-icon-mobile data-section=download> <span class="f1r-icon icon-76_download_file white"></span> </div> <div class="article-tools-icon-mobile mobile-metrics article-metrics-wrapper metrics-icon-wrapper" data-section=metrics data-version-id=26833 data-id=24320 data-downloads="" data-views="" data-scholar="10.12688/f1000research.24320.1" data-recommended="" data-f1r-ga-helper="Article Page Metrics (Mobile)"> <span class="f1r-icon icon-89_metrics white"></span> </div> <div class=article-tools-divider-mobile></div> <div class=article-tools-icon-mobile data-section=cite> <span class="f1r-icon icon-82_quote white"></span> </div> <div class="article-tools-icon-mobile " data-section=track> <span class="f1r-icon icon-90_track white"></span> </div> <div class=article-tools-divider-mobile></div> <div class=article-tools-icon-mobile data-section=share> <span class="f1r-icon icon-34_share white"></span> </div> <span class=article-toolbox-stretch></span> </div> <div class=article-toolbox-content-mobile> <div class="toolbox-section download"> <div class=toolbox-section-heading>Download</div> <div class=toolbox-section-content> <a href="https://f1000research.com/articles/9-680/v1/pdf?article_uuid=42c4b4ec-2cad-4876-a4ea-1277540a9d7e" title="Download PDF" class="no-decoration pdf-download-helper"> <span class="f1r-icon icon-102_download_pdf toolbox-section-icon"></span> </a> <div class=toolbox-section-option-divider>&nbsp;</div> <a id=mobile-download-xml class=no-decoration href="#" title="Download XML"> <span class="f1r-icon icon-103_download_xml toolbox-section-icon"></span> </a> </div> <div class=toolbox-section-divider></div> <div class=toolbox-section-heading>Export To</div> <div class=toolbox-section-content> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=WORKSPACE>Sciwheel</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=BIBTEX>Bibtex</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=ENDNOTE>EndNote</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=PROCITE>ProCite</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=REF_MANAGER>Ref. Manager (RIS)</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=SENTE>Sente</button> </div> </div> <div class="toolbox-section metrics"> <div class="toolbox-section-heading no-top-border">metrics</div> <div class="toolbox-section-divider toolbox-section-divider--no-height"></div> <div class=article-metrics-pageinfo> <div class=c-article-metrics-table> <table class=c-article-metrics-table__table> <thead> <tr> <th></th> <th><span class=c-article-metrics-table__heading>Views</span></th> <th><span class=c-article-metrics-table__heading>Downloads</span></th> </tr> </thead> <tbody> <tr> <th class=c-article-metrics-table__row-heading><span class="c-article-metrics-table__platform u-platform--" data-test-id=metrics_platform_name_mob>F1000Research</span></th> <td class="c-article-metrics-table__value js-article-views-count" data-test-id=metrics_platform_views_mob>-</td> <td class="c-article-metrics-table__value js-article-downloads-count" data-test-id=metrics_platform_downloads_mob>-</td> </tr> <tr> <th class=c-article-metrics-table__row-heading> <span class="u-ib u-middle c-article-metrics-table__pmc" data-test-id=metrics_pmc_name_mob>PubMed Central</span> <div class="c-block-tip c-block-tip--centered c-article-metrics-table__tooltip c-block-tip--md-padding c-block-tip--small-arrow u-ib u-middle"> <button type=button class="u-black--medium u-black--high@hover u-ib u-middle c-button--icon c-button--text c-block-tip__toggle"><i class="material-icons c-button--icon__icon">info_outline</i></button> <div class=c-block-tip__content>Data from PMC are received and updated monthly.</div> </div> </th> <td class="c-article-metrics-table__value js-pmc-views-count" data-test-id=metrics_pmc_views_mob>-</td> <td class="c-article-metrics-table__value js-pmc-downloads-count" data-test-id=metrics_pmc_downloads_mob>-</td> </tr> </tbody> </table> </div> </div> <span class=metrics-citations-container> <div class=toolbox-section-divider></div> <div class="toolbox-section-heading u-mb--1">Citations</div> <div> <div class=toolbox-section-colsplit> <div class=citations-scopus-logo> <a href="" target=_blank class="is-hidden metrics-citation-icon" title="View full citation details at www.scopus.com"><i class="material-icons scopus-icon">open_in_new</i></a> </div> <div class="toolbox-section-count scopus"> <a href='' class='scopus-citation-link is-hidden' target=_blank title='View full citation details at www.scopus.com'>0</a> </div> </div> <div class=toolbox-section-colsplit> <div class="citations-pubmed-logo f1000research"> <a href="" target=_blank class="is-hidden metrics-citation-icon f1000research" title="View full citation details"><i class="material-icons scopus-icon">open_in_new</i></a> </div> <div class="toolbox-section-count pubmed"> <a href='' class='pubmed-citation-link is-hidden' target=_blank title='View full citation details'>0</a> </div> </div> <div class=toolbox-section-divider></div> <div class=toolbox-section-content> <div class="citations-scholar-logo f1000research"> <a href="" target=_blank class="is-hidden metrics-citation-icon google-scholar f1000research" title="View full citation details" data-scholar="10.12688/f1000research.24320.1"><i class="material-icons scopus-icon">open_in_new</i></a> </div> </div> </div> </span> <span class=metrics-details-container> <div class=toolbox-section-divider></div> <div class="toolbox-section-content altmetric-section"> <div class=altmetrics-image></div> <div class=altmetrics-more-link> <a href="" target=_blank class=f1r-standard-link>SEE MORE DETAILS</a> </div> <div class=altmetric-mobile-column-counts></div> <div class=altmetric-mobile-column-readers></div> <div class=toolbox-section-divider></div> </div> </span> </div> <div class="toolbox-section cite"> <div class="toolbox-section-heading no-top-border">CITE</div> <div class=toolbox-section-divider></div> <div class=toolbox-section-heading>how to cite this article</div> <div id=citation-copy-mobile class="toolbox-section-content text-content heading9 small" data-test-id=mob_copy-citation_text> Ogeto T, Ndubi F, Murithi M <em>et al.</em> Malaria vaccines targeting the pre-erythrocytic stage: a scoping review [version 1; peer review: awaiting peer review] <i>F1000Research</i> 2020, <b>9</b>:680 (<a href="https://doi.org/10.12688/f1000research.24320.1" target=_blank>https://doi.org/10.12688/f1000research.24320.1</a>) </div> <div class=toolbox-section-divider></div> <div class="toolbox-section-content text-content heading9 small"> NOTE: <em>it is important to ensure the information in <b>square brackets after the title</b> is included in all citations of this article.</em> </div> <div class=toolbox-section-content> <button class="primary orange extra-padding copy-cite-article-mobile js-clipboard" data-clipboard-target="#citation-copy-mobile" title="Copy the current citation details." data-test-id=mob_copy-citation_button-mob>COPY CITATION DETAILS</button> </div> </div> <div class="toolbox-section track"> <div class="toolbox-section-heading no-top-border">track</div> <div class=toolbox-section-divider></div> <div class=toolbox-section-heading>receive updates on this article</div> <div class="toolbox-section-content padding-left-20 padding-right-20 heading9 small"> Track an article to receive email alerts on any updates to this article. </div> <div class=toolbox-section-content> <a data-article-id=24320 id=mobile-track-article-signin-24320 title="Receive updates on new activity such as publication of new versions, peer reviews or author responses." href="/login?originalPath=/trackArticle/24320?target=/articles/9-680.html"> <button class="primary orange extra-padding"> TRACK THIS ARTICLE </button> </a> </div> </div> <div class="toolbox-section share"> <div class="toolbox-section-heading no-top-border">Share</div> <div class=toolbox-section-divider></div> <div class=toolbox-section-content> <a target=_blank class="f1r-shares-icon-square f1r-shares-email" title="Email this article"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-twitter" title="Share on Twitter"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-facebook" title="Share on Facebook"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-linkedin" title="Share on LinkedIn"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-reddit" title="Share on Reddit"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-mendelay" title="Share on Mendeley"></a> <div class="email-article-wrapper email-article-version-container"> <div class=toolbox-section-divider></div> <script src='https://www.recaptcha.net/recaptcha/api.js'></script> <form class="recommend-version-form-mobile research-layout"> <p>All fields are required.</p> <input name=versionId type=hidden value=26833 /> <input name=articleId type=hidden value=24320 /> <input name=senderName class="form-input-field reg-form" value="" type=text placeholder="Your name"/> <input name=senderEmail class="form-input-field reg-form margin-top" value="" type=text placeholder="Your email address"/> <textarea name=recipientEmails class="form-textarea-field ninetynine-percent-wide margin-top no-resize" placeholder="Recipient email address(es) (comma delimited)"></textarea> <input class="form-input-field reg-form margin-top" name=subject type=text value="Interesting article on F1000Research" placeholder=Subject /> <textarea name=message class="form-textarea-field reg-form margin-top no-resize">I thought this article from F1000Research (https://f1000research.com) would be of interest to you.</textarea> <div class="g-recaptcha margin-top" data-sitekey=6LcHqxoUAAAAANP3_0TzpGG6qFvl4DhbUcuRzw7W></div> <input value="" name=captcha type=hidden /> <p>A full article citation will be automatically included.</p> <p><img class="ticker-email-article-details hidden" src="/img/ticker.gif" alt=loading /></p> <button class="secondary orange margin-bottom" data-test-id=version_share_email_send>SEND EMAIL</button> <div class="orange-message margin-bottom is-hidden" data-test-id=version_share_email_message></div> </form> </div> </div> </div> </div> </div> <a name=article-reports></a> <div id=article-reports class="u-mt--3 reports-comments no-divider"> <div class="current-referee-status no-border-and-margin "> <h2 class=main-title id=current-referee-status> <span class="research-layout f1r-article-mobile-inline valign-middle"> <span class="f1r-icon icon-85_peer_review size30"></span> </span> Open Peer Review <span class="f1r-article-mobile-inline float-right"> <span class="f1r-icon icon-14_more_small"></span> <span class="f1r-icon icon-10_less_small"></span> </span> </h2> <a name=current-referee-status></a> <div class=current-referee-status__content name=add-new-report-comment id=add-new-report-comment> Current Reviewer Status: <div class=f1r-article-desk-inline><em>AWAITING PEER REVIEW</em></div> <div class="f1r-article-mobile-inline float-right"><em>AWAITING PEER REVIEW</em></div> <span class="circle-icon-small to-right" data-window=about-referee-status title=Help>?</span> <span class="research-layout f1r-article-mobile"> <div class=mobile-ref-status-help> Key to Reviewer Statuses <span class=referee-status-pointer></span> <span class="view-control float-right">VIEW</span> <span class="view-control float-right is-hidden">HIDE</span> <div class=mobile-ref-status-help-content> <div class="cf margin-top"> <span class="f1r-icon icon-86_approved status-green smaller float-left margin-bottom-40 margin-right" title=Approved></span> <span class=title>Approved</span>The paper is scientifically sound in its current form and only minor, if any, improvements are suggested </div> <div class="cf margin-top"> <span class="f1r-icon icon-87_approved_reservations status-green smaller float-left margin-bottom-40 margin-right" title="Approved with Reservations"></span> <span class=title>Approved with reservations</span> A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit. </div> <div class="cf margin-top"> <span class="f1r-icon icon-88_not_approved status-red small float-left margin-bottom-30 margin-right" title="Not Approved"></span> <span class=title>Not approved</span>Fundamental flaws in the paper seriously undermine the findings and conclusions </div> </div> </div> </span> </div> </div> </div> <div class="f1r-article-mobile research-layout"> <div class="mobile-sections-divider before-comments"></div> </div> <div id=article-comments class="article-comments padding-bottom-20"> <div class=current-article-comment-section> <h2 class=main-title name=add-new-comment id=add-new-comment> <span class="research-layout f1r-article-mobile-inline valign-middle"> <span class="f1r-icon icon-104_comments size30"></span> </span> <span class=f1r-article-desk-inline>Comments on this article</span> <span class=f1r-article-mobile-inline>Comments (0)</span> <span class="f1r-article-mobile-inline float-right"> <span class="f1r-icon icon-14_more_small"></span> <span class="f1r-icon icon-10_less_small"></span> </span> </h2> </div> <div class="f1r-article-desk-inline referee-report-info-box referee-report-version-box"> Version 1 </div> <div class="f1r-article-mobile research-layout mobile-version-info padding-top-30"> <span class=mversion>VERSION 1</span> <span class=details>PUBLISHED 07 Jul 2020</span> <span class="article-pubinfo-mobile versions-section"> </span> </div> <div class="f1r-article-mobile research-layout margin-top-20 is-centered"> <a href="/login?originalPath=/articles/9-680.html&scrollTo=add-new-comment" class=register-report-comment-button data-test-id=add-comment_mob> <button class="primary orange extra-padding comment-on-this-report">ADD YOUR COMMENT</button> </a> </div> <a href="/login?originalPath=/articles/9-680.html&scrollTo=add-new-comment" class="f1r-article-desk register-report-comment-button" data-test-id=add-comment> <span class=contracted></span>Comment </a> </div> </div> </div> <div id=article_main-column class="p-article__sidebar o-layout__item u-1/3 not-expanded js-article-sidebar"> <div class="o-tab p-article__column-toggle-container"> <button class="c-tab c-tab--left js-column-toggle p-article__column-toggle not-expanded " type=button data-target-main=article_main-column data-target-secondary=article_secondary-column><i class="c-tab__icon material-icons u-hide@expanded">keyboard_arrow_left</i><i class="c-tab__icon material-icons u-show@expanded">keyboard_arrow_right</i></button> </div> <div class=p-article__sidebar-content> <div class="p-article__sidebar-scroller js-article-sidebar-scroller"> <section class="p-article__sidebar-view js-article-sidebar-view js-article-sidebar-main u-pt u-pb--8" data-view=peer-review> <div class="o-layout o-layout--flush"> <div class="o-layout__item u-pl"> <h3 class="u-mt--0 u-mb--2 t-h3 u-weight--md u-pl" data-test-id=article_sidebar_heading>Open Peer Review</h3> </div> <div class=o-layout__item> <div class="p-article__sidebar-highlight u-mb--2"> <h4 class="u-mt--0 u-mb--0 u-ib u-middle t-h4 u-weight--md u-mr--1/2">Reviewer Status</h4> <div class="u-ib u-middle"><em>AWAITING PEER REVIEW</em></div> </div> </div> <section class="o-layout__item u-pl"> <div class=u-pl> <hr class="c-hr c-hr--low c-hr--md u-mb--3"> <h4 class="t-h3 u-weight--md u-mt--0 u-mb--2">Comments on this article</h4> <div class=u-mb--4> <p class="u-mt--0 u-mb--1 t-h4"><a class=p-article__color--light href="#article-comments">All Comments</a><span class=" u-ib u-ml--1/2 p-article__color--light">(0)</span></p> <a class=t-h4 href="/login?originalPath=/articles/9-680.html&scrollTo=add-new-comment" data-test-id=add-comment>Add a comment</a> </div> <hr class="c-hr c-hr--low c-hr--md u-mb--4"> <div class="research-layout f1r-article-desk"> <div class="heading6 c-ribbon-wrapper c-ribbon-wrapper--etoc f1000research "> <div class=c-ribbon-wrapper__body>Sign up for content alerts</div> </div> </div> <div class="research-layout sidebar-sign-up-form f1r-article-desk u-mb--4 "> <form class=js-email-alert-signup action="#" method=POST data-email=tocAlertWeekly> <input type=hidden name=isUserLoggedIn class=js-email-alert-signup-logged-in value=N /> <input type=hidden name=userId class=js-email-alert-signup-user-id value=""/> <input type=hidden name=frequency class=js-email-alert-signup-frequency value=WEEKLY /> <div class="o-actions o-actions--middle"> <div class=o-actions__primary> <input type=email name=emailAddress class="form-input-field js-email-alert-signup-address u-1/1 u-bb" required=required placeholder=Email /> </div> <div class=o-actions__secondary> <div class="_mdl-layout u-ml--1/2"> <button class="mdl-button mdl-js-button mdl-button--colored mdl-button--small mdl-button--filled js-email-alert-signup-submit">Sign Up</button> </div> </div> </div> </form> <div id=sidebar-sign-up-message class="section-text js-email-alert-signup-msg is-hidden">You are now signed up to receive this alert</div> </div> <section class=js-terms-container> <hr class="c-hr c-hr--low c-hr--md u-mb--3"> <h4 class="t-h3 u-weight--md u-mt--0 u-mb--1">Browse by related subjects</h4> <div class="article-subcontainer article-subcontainer--sidebar"> <ul class=js-terms-list></ul> </div> </section> </div> </section> </div> </section> </div> <script src="/js/shared_scripts/modal-dialogue.js"></script> <script src="/js/shared_scripts/read-more.js"></script> <script src="/js/article/article-router.js"></script> <script src="/js/article/article-sidebar.js"></script> <script src="/js/referee/new/referee_helpers.js"></script> <script src="/js/article/article-column-toggle.js"></script> </div> </div> </div> </main> <input type=hidden id=_articleVersionUrl value="https://f1000research.com/articles/9-680/v1/"> <div class=research-help id=about-referee-status> <div class="research-layout research-help-content about-referee-status"> <span class="close-research-help dark-cross" title=Close></span> Alongside their report, reviewers assign a status to the article: <div class="cf research-help-row"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> <span class=research-help-text>Approved - the paper is scientifically sound in its current form and only minor, if any, improvements are suggested</span> </div> <div class="cf research-help-row"> <span class="f1r-icon icon-87_approved_reservations status-green smaller" title="Approved with Reservations"></span> <span class=research-help-text>Approved with reservations - A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit. </span> </div> <div class="cf research-help-row"> <span class="f1r-icon icon-88_not_approved status-red small" title="Not Approved"></span> <span class=research-help-text>Not approved - fundamental flaws in the paper seriously undermine the findings and conclusions</span> </div> </div> </div> <div id=datasets-info class=is-hidden> </div> <div class=article-interactive-content-container style="display: none;"> <a name=f-template class=n-a></a> <div class="interactive-content-wrapper padding-20"> <img src="" class=interactive-content-image title="Open the interactive image display"> <div class=interactive-content-title></div> <div class=interactive-content-text></div> <div class="f1r-article-desk interactive-content-ribbon" data-interactive-content-type=R-Script> <div class=interactive-content-label>Adjust parameters to alter display</div> <div class=interactive-content-button></div> </div> <div class="f1r-article-mobile mobile-interactive-note"> View on desktop for interactive features <img src="/img/icon/interactive_content.png" class="float-right margin-right-40"/> </div> <div class=clearfix></div> </div> </div> <div id=article-interactive-omero-container class=article-interactive-omero-container style="display: none;"> <div class=interactive-content-wrapper> <div class="interactive-omero-button omero-content" title="Open the interactive content window." data-interactive-content-type=Omero></div> <div class=has-interactive-content-image> <span class=box-arrow></span> <span class=box-middle>Includes Interactive Elements</span> <span class=box-end></span> </div> <div class="fig panel clearfix" style="margin: 0; padding-bottom: 20px;"> <a name=templatelink class=n-a></a> <a target=_blank href="" class=link-for-omero-image> <img src="" class=interactive-omero-image title="Open the image display window."> </a> <div class=caption> <div class=interactive-content-title></div> <div class=interactive-content-text></div> </div> <div class="is-hidden omero-image-list"></div> </div> <div class="f1r-article-mobile mobile-interactive-note omero"> View on desktop for interactive features <img src="/img/icon/interactive_content.png" class="float-right margin-right-40"/> </div> <div class=clearfix></div> </div> </div> <div class="add-comment-container shadow-box is-hidden" id=save-comment-container> <span id=save-comment-text class=intro-text>Edit comment</span> <textarea id=new-comment name=new-comment class="global-textarea comment margin-bottom margin-top"></textarea> <p><strong>Competing Interests</strong></p> <textarea id=new-competing-interests name=competing-interests class="global-textarea competing-interests margin-bottom check-xss"></textarea> <div class=clearfix></div> <button id=cancelComment type=button class="general-white-orange-button float-right no-background-button margin-left"> Cancel </button> <button id=save-comment-button commentId="" type=button class="general-white-orange-button float-right"> Save </button> <div class=clearfix></div> <div class="green-message margin-top is-hidden comment-is-saved">The comment has been saved.</div> <div class="red-message margin-top is-hidden comment-not-added">An error has occurred. Please try again.</div> <div class="red-message margin-top is-hidden comment-enter-text ucf">Your must enter a comment.</div> <div class="red-message margin-top is-hidden comment-references-error references">References error.</div> </div> <div class="modal-window-wrapper is-hidden"> <div id=conflicts-interests class="modal-window padding-20"> <div class=modal-window__content> <h2 class=h2-title>Competing Interests Policy</h2> <p> Provide sufficient details of any financial or non-financial competing interests to enable users to assess whether your comments might lead a reasonable person to question your impartiality. Consider the following examples, but note that this is not an exhaustive list: </p> <div class=heading5>Examples of 'Non-Financial Competing Interests'</div> <ol class="numbered-list no-padding"> <li class=standard-padding>Within the past 4 years, you have held joint grants, published or collaborated with any of the authors of the selected paper.</li> <li class=standard-padding>You have a close personal relationship (e.g. parent, spouse, sibling, or domestic partner) with any of the authors.</li> <li class=standard-padding>You are a close professional associate of any of the authors (e.g. scientific mentor, recent student).</li> <li class=standard-padding>You work at the same institute as any of the authors.</li> <li class=standard-padding>You hope/expect to benefit (e.g. favour or employment) as a result of your submission.</li> <li class=standard-padding>You are an Editor for the journal in which the article is published.</li> </ol> <div class="heading5 padding-top">Examples of 'Financial Competing Interests'</div> <ol class="numbered-list no-padding"> <li class=standard-padding>You expect to receive, or in the past 4 years have received, any of the following from any commercial organisation that may gain financially from your submission: a salary, fees, funding, reimbursements.</li> <li class=standard-padding>You expect to receive, or in the past 4 years have received, shared grant support or other funding with any of the authors.</li> <li class=standard-padding>You hold, or are currently applying for, any patents or significant stocks/shares relating to the subject matter of the paper you are commenting on.</li> </ol> </div> <div class="f1r-article-mobile research-layout"> <span class=modal-window-close-button></span> </div> </div> </div> <div class="o-modal c-email-alert-popup js-email-alert-popup is-hidden"> <div class="o-modal__body js-modal-body c-email-alert-popup__inner"> <h3 class=c-email-alert-popup__title>Stay Updated</h3> <p class=c-email-alert-popup__sub>Sign up for content alerts and receive a weekly or monthly email with all newly published articles</p> <p><a href="/register?originalPath=" class="c-email-alert-popup__lnk c-email-alert-popup__button js-email-alert-popup-action">Register with F1000Research</a></p> <p>Already registered? <a href="/login?originalPath=" class="c-email-alert-popup__lnk js-email-alert-popup-action">Sign in</a></p> <p class=c-email-alert-popup__footer><a class="c-email-alert-popup__lnk js-email-alert-popup-cancel" href="#">Not now, thanks</a></p> </div> </div> <div id=addCommentModal role=dialog aria-labelledby=addCommentModal_title aria-describedby=addCommentModal_description> <div class="c-modal js-modal is-closed p-article__add-comment-modal c-modal--xlarge js-article-comment-modal c-modal--scroll "> <aside class="c-modal__content u-black--high o-box u-pb--0 u-bg--2 c-modal--scroll-always "> <div class=c-modal__close> <button type=button class="c-button c-button--icon c-button--medium c-button--full@hover js-modal__close"><i class="c-button--icon__icon material-icons">close</i></button> </div> <div id=addCommentModal_description class="c-modal__description js-modal__content t-h4 u-mt--0 u-mb--2 u-black--medium"> <div class="js-add-comment-container t-caption u-black--high"> <div class=u-weight--bd>PLEASE NOTE</div> <div class=u-mt--1> <span class="red u-weight--bd">If you are an AUTHOR of this article,</span> please check that you signed in with the account associated with this article otherwise we cannot automatically identify your role as an author and your comment will be labelled as a &ldquo;User Comment&rdquo;. </div> <div class=u-mt--1> <span class="red u-weight--bd">If you are a REVIEWER of this article,</span> please check that you have signed in with the account associated with this article and then go to your <a href="/my/referee">account</a> to submit your report, please do not post your review here. </div> <div class="u-mt--1 u-mb--1"> If you do not have access to your original account, please <a href="mailto:research@f1000.com">contact us</a>. </div> <p class=no-top-margin>All commenters must hold a formal affiliation as per our <a href="/about/policies#commentspolicy" target=_blank>Policies</a>. The information that you give us will be displayed next to your comment.</p> <p>User comments must be in English, comprehensible and relevant to the article under discussion. We reserve the right to remove any comments that we consider to be inappropriate, offensive or otherwise in breach of the <a href="/about/legal/usercommenttermsandconditions" target=_blank>User Comment Terms and Conditions</a>. Commenters must not use a comment for personal attacks. When criticisms of the article are based on unpublished data, the data should be made available.</p> <div class="comments-note margin-bottom" id=accept-user-comments> <input class=js-add-comment-accept-terms type=checkbox id=acceptedTermsAndConditions name=acceptedTermsAndConditions> I accept the <a href="/about/legal/usercommenttermsandconditions" target=_blank> User Comment Terms and Conditions</a> <span class=required>&nbsp;</span> </div> <div class="default-error margin-top is-hidden comment-accept-conditions utac">Please confirm that you accept the User Comment Terms and Conditions.</div> <div class="research-layout registration-form u-mb--2"> <div class="u-mb--1 u-mt--2"> <strong>Affiliation</strong> </div> <div class=form-field> <input type=text name=institution class="form-input-field check-xss js-add-comment-institution" placeholder="Organization *" autocomplete=off /> <div class="default-error margin-top is-hidden comment-enter-institution institution">Please enter your organisation.</div> </div> <div class=form-field> <input type=text name=place class="form-input-field check-xss js-add-comment-place" placeholder=Place> </div> <div class=form-field> <div class="form-input-wrapper hundred-percent-wide"> <div class="new-select-standard-wrapper half-width inline-display heading10"> <select name=countryId id=country class="form-select-menu smaller js-add-comment-country"> <option value=-1>Country*</option> <option value=840>USA</option> <option value=826>UK</option> <option value=124>Canada</option> <option value=156>China</option> <option value=250>France</option> <option value=276>Germany</option> <optgroup label=-----------------------------------------------></optgroup> <option value=4>Afghanistan</option> <option value=248>Aland Islands</option> <option value=8>Albania</option> <option value=12>Algeria</option> <option value=16>American Samoa</option> <option value=20>Andorra</option> <option value=24>Angola</option> <option value=660>Anguilla</option> <option value=10>Antarctica</option> <option value=28>Antigua and Barbuda</option> <option value=32>Argentina</option> <option value=51>Armenia</option> <option value=533>Aruba</option> <option value=36>Australia</option> <option value=40>Austria</option> <option value=31>Azerbaijan</option> <option value=44>Bahamas</option> <option value=48>Bahrain</option> <option value=50>Bangladesh</option> <option value=52>Barbados</option> <option value=112>Belarus</option> <option value=56>Belgium</option> <option value=84>Belize</option> <option value=204>Benin</option> <option value=60>Bermuda</option> <option value=64>Bhutan</option> <option value=68>Bolivia</option> <option value=70>Bosnia and Herzegovina</option> <option value=72>Botswana</option> <option value=74>Bouvet Island</option> <option value=76>Brazil</option> <option value=86>British Indian Ocean Territory</option> <option value=92>British Virgin Islands</option> <option value=96>Brunei</option> <option value=100>Bulgaria</option> <option value=854>Burkina Faso</option> <option value=108>Burundi</option> <option value=116>Cambodia</option> <option value=120>Cameroon</option> <option value=124>Canada</option> <option value=132>Cape Verde</option> <option value=136>Cayman Islands</option> <option value=140>Central African Republic</option> <option value=148>Chad</option> <option value=152>Chile</option> <option value=156>China</option> <option value=162>Christmas Island</option> <option value=166>Cocos (Keeling) Islands</option> <option value=170>Colombia</option> <option value=174>Comoros</option> <option value=178>Congo</option> <option value=184>Cook Islands</option> <option value=188>Costa Rica</option> <option value=384>Cote d'Ivoire</option> <option value=191>Croatia</option> <option value=192>Cuba</option> <option value=196>Cyprus</option> <option value=203>Czech Republic</option> <option value=180>Democratic Republic of the Congo</option> <option value=208>Denmark</option> <option value=262>Djibouti</option> <option value=212>Dominica</option> <option value=214>Dominican Republic</option> <option value=218>Ecuador</option> <option value=818>Egypt</option> <option value=222>El Salvador</option> <option value=226>Equatorial Guinea</option> <option value=232>Eritrea</option> <option value=233>Estonia</option> <option value=231>Ethiopia</option> <option value=238>Falkland Islands</option> <option value=234>Faroe Islands</option> <option value=583>Federated States of Micronesia</option> <option value=242>Fiji</option> <option value=246>Finland</option> <option value=250>France</option> <option value=254>French Guiana</option> <option value=258>French Polynesia</option> <option value=260>French Southern Territories</option> <option value=266>Gabon</option> <option value=268>Georgia</option> <option value=276>Germany</option> <option value=288>Ghana</option> <option value=292>Gibraltar</option> <option value=300>Greece</option> <option value=304>Greenland</option> <option value=308>Grenada</option> <option value=312>Guadeloupe</option> <option value=316>Guam</option> <option value=320>Guatemala</option> <option value=831>Guernsey</option> <option value=324>Guinea</option> <option value=624>Guinea-Bissau</option> <option value=328>Guyana</option> <option value=332>Haiti</option> <option value=334>Heard Island and Mcdonald Islands</option> <option value=336>Holy See (Vatican City State)</option> <option value=340>Honduras</option> <option value=344>Hong Kong</option> <option value=348>Hungary</option> <option value=352>Iceland</option> <option value=356>India</option> <option value=360>Indonesia</option> <option value=364>Iran</option> <option value=368>Iraq</option> <option value=372>Ireland</option> <option value=376>Israel</option> <option value=380>Italy</option> <option value=388>Jamaica</option> <option value=392>Japan</option> <option value=832>Jersey</option> <option value=400>Jordan</option> <option value=398>Kazakhstan</option> <option value=404>Kenya</option> <option value=296>Kiribati</option> <option value=901>Kosovo (Serbia and Montenegro)</option> <option value=414>Kuwait</option> <option value=417>Kyrgyzstan</option> <option value=418>Lao People's Democratic Republic</option> <option value=428>Latvia</option> <option value=422>Lebanon</option> <option value=426>Lesotho</option> <option value=430>Liberia</option> <option value=434>Libya</option> <option value=438>Liechtenstein</option> <option value=440>Lithuania</option> <option value=442>Luxembourg</option> <option value=446>Macao</option> <option value=807>Macedonia</option> <option value=450>Madagascar</option> <option value=454>Malawi</option> <option value=458>Malaysia</option> <option value=462>Maldives</option> <option value=466>Mali</option> <option value=470>Malta</option> <option value=584>Marshall Islands</option> <option value=474>Martinique</option> <option value=478>Mauritania</option> <option value=480>Mauritius</option> <option value=175>Mayotte</option> <option value=484>Mexico</option> <option value=581>Minor Outlying Islands of the United States</option> <option value=498>Moldova</option> <option value=492>Monaco</option> <option value=496>Mongolia</option> <option value=499>Montenegro</option> <option value=500>Montserrat</option> <option value=504>Morocco</option> <option value=508>Mozambique</option> <option value=104>Myanmar</option> <option value=516>Namibia</option> <option value=520>Nauru</option> <option value=524>Nepal</option> <option value=530>Netherlands Antilles</option> <option value=540>New Caledonia</option> <option value=554>New Zealand</option> <option value=558>Nicaragua</option> <option value=562>Niger</option> <option value=566>Nigeria</option> <option value=570>Niue</option> <option value=574>Norfolk Island</option> <option value=580>Northern Mariana Islands</option> <option value=408>North Korea</option> <option value=578>Norway</option> <option value=512>Oman</option> <option value=586>Pakistan</option> <option value=585>Palau</option> <option value=275>Palestinian Territory</option> <option value=591>Panama</option> <option value=598>Papua New Guinea</option> <option value=600>Paraguay</option> <option value=604>Peru</option> <option value=608>Philippines</option> <option value=612>Pitcairn</option> <option value=616>Poland</option> <option value=620>Portugal</option> <option value=630>Puerto Rico</option> <option value=634>Qatar</option> <option value=638>Reunion</option> <option value=642>Romania</option> <option value=643>Russian Federation</option> <option value=646>Rwanda</option> <option value=654>Saint Helena</option> <option value=659>Saint Kitts and Nevis</option> <option value=662>Saint Lucia</option> <option value=666>Saint Pierre and Miquelon</option> <option value=670>Saint Vincent and the Grenadines</option> <option value=882>Samoa</option> <option value=674>San Marino</option> <option value=678>Sao Tome and Principe</option> <option value=682>Saudi Arabia</option> <option value=686>Senegal</option> <option value=688>Serbia</option> <option value=690>Seychelles</option> <option value=694>Sierra Leone</option> <option value=702>Singapore</option> <option value=703>Slovakia</option> <option value=705>Slovenia</option> <option value=90>Solomon Islands</option> <option value=706>Somalia</option> <option value=710>South Africa</option> <option value=239>South Georgia and the South Sandwich Is</option> <option value=410>South Korea</option> <option value=724>Spain</option> <option value=144>Sri Lanka</option> <option value=736>Sudan</option> <option value=740>Suriname</option> <option value=744>Svalbard and Jan Mayen</option> <option value=748>Swaziland</option> <option value=752>Sweden</option> <option value=756>Switzerland</option> <option value=760>Syria</option> <option value=158>Taiwan</option> <option value=762>Tajikistan</option> <option value=834>Tanzania</option> <option value=764>Thailand</option> <option value=270>The Gambia</option> <option value=528>The Netherlands</option> <option value=626>Timor-Leste</option> <option value=768>Togo</option> <option value=772>Tokelau</option> <option value=776>Tonga</option> <option value=780>Trinidad and Tobago</option> <option value=788>Tunisia</option> <option value=792>Turkey</option> <option value=795>Turkmenistan</option> <option value=796>Turks and Caicos Islands</option> <option value=798>Tuvalu</option> <option value=800>Uganda</option> <option value=826>UK</option> <option value=804>Ukraine</option> <option value=784>United Arab Emirates</option> <option value=850>United States Virgin Islands</option> <option value=858>Uruguay</option> <option value=840>USA</option> <option value=860>Uzbekistan</option> <option value=548>Vanuatu</option> <option value=862>Venezuela</option> <option value=704>Vietnam</option> <option value=876>Wallis and Futuna</option> <option value=905>West Bank and Gaza Strip</option> <option value=732>Western Sahara</option> <option value=887>Yemen</option> <option value=894>Zambia</option> <option value=716>Zimbabwe</option> </select> </div> </div> <div class="default-error margin-top is-hidden comment-enter-country country">Please select your country.</div> </div> </div> <textarea data-test-id=article_add-comment_comment name=new-comment class="js-add-comment-comment comment margin-bottom margin-top"></textarea> <div class="default-error margin-top comment-enter-text comment-error is-hidden ">You must enter a comment.</div> <label class="comments-note u-mt--2 u-mb--2" for=competingInterests_1> <div class="u-mb--1 u-mt--2"><strong data-test-id=article_report-add-comment_competing-interests-title>Competing Interests</strong></div> <p class="u-mb--2 u-mt--0" data-test-id=article_report-add-comment_competing-interests-description>Please disclose any <a href="#article-competing-intersts-policy" class=js-modal-competing-intersts-toggle>competing interests</a> that might be construed to influence your judgment of the article's or peer review report's validity or importance.</p> </label> <div id=article-competing-intersts-policy class=js-article-competing-interests-policy style="display: none;"> <h2 class="h2-title u-mt--0 u-pt--0">Competing Interests Policy</h2> <p> Provide sufficient details of any financial or non-financial competing interests to enable users to assess whether your comments might lead a reasonable person to question your impartiality. Consider the following examples, but note that this is not an exhaustive list: </p> <div class=heading5>Examples of 'Non-Financial Competing Interests'</div> <ol class="numbered-list no-padding"> <li class=standard-padding>Within the past 4 years, you have held joint grants, published or collaborated with any of the authors of the selected paper.</li> <li class=standard-padding>You have a close personal relationship (e.g. parent, spouse, sibling, or domestic partner) with any of the authors.</li> <li class=standard-padding>You are a close professional associate of any of the authors (e.g. scientific mentor, recent student).</li> <li class=standard-padding>You work at the same institute as any of the authors.</li> <li class=standard-padding>You hope/expect to benefit (e.g. favour or employment) as a result of your submission.</li> <li class=standard-padding>You are an Editor for the journal in which the article is published.</li> </ol> <div class="heading5 padding-top">Examples of 'Financial Competing Interests'</div> <ol class="numbered-list no-padding"> <li class=standard-padding>You expect to receive, or in the past 4 years have received, any of the following from any commercial organisation that may gain financially from your submission: a salary, fees, funding, reimbursements.</li> <li class=standard-padding>You expect to receive, or in the past 4 years have received, shared grant support or other funding with any of the authors.</li> <li class=standard-padding>You hold, or are currently applying for, any patents or significant stocks/shares relating to the subject matter of the paper you are commenting on.</li> </ol> </div> <div id=competingInterests_1 class="c-inline-editor js-inline-editor js-form_input u-bb--all u-mb--2 js-comment-competing-interests" data-name=competing-interests data-rows=3> <textarea id=competingInterests_1_input name=competing-interests placeholder="&nbsp;" required=false class="u-hide-visually js-inline-editor_input" tabindex=-1></textarea> <div class="c-inline-editor__editor js-inline-editor_editor o-box c-box o-box--tiny u-bg--11" data-target=competingInterests_1_input role=textbox required=false data-placeholder="&nbsp;" contenteditable=true></div> <span class="c-inline-editor__error js-inline-editor-message">Please state your competing interests</span> </div> <div data-test-id=article_add-comment_saved class="green-message comments is-hidden comment-is-saved">The comment has been saved.</div> <div data-test-id=article_add-comment_error class="default-error comments is-hidden comment-not-added">An error has occurred. Please try again.</div> <div class=clearfix></div> <div class=js-hook></div> </div> <div class="c-modal__extra-message js-modal__extra-message t-h4 u-black--medium"></div></div> <div class="c-modal__actions o-box__actions"> <a href="#" data-test-id=article_add-comment_cancel class="c-button c-button--full js-modal__close c-button--secondary">Cancel</a> <a href="#" data-test-id=article_add-comment_post class="c-button c-button--full js-modal__confirm c-button--primary">Post</a> </div> </aside> </div> </div> <style>
                .at-icon-wrapper {
        background-size: 100% !important;
    }
</style> <script src="/js/namespace.js"></script> <script src="/js/constants.js"></script> <script src="/js/utilities.js"></script> <script src="/js/article/alert-signup.js"></script> <script type='text/javascript'>
    var lTitle = "Malaria vaccines targeting the pre-erythrocytic...".replace("'", '');
    var linkedInUrl = "http://www.linkedin.com/shareArticle?url=https://f1000research.com/articles/9-680/v1" + "&title=" + encodeURIComponent(lTitle) + "&summary=" + encodeURIComponent('Read the article by ');

    var deliciousUrl = "https://del.icio.us/post?url=https://f1000research.com/articles/9-680/v1&title=" + encodeURIComponent(lTitle);

    var redditUrl = "http://reddit.com/submit?url=https://f1000research.com/articles/9-680/v1" + "&title=" + encodeURIComponent(lTitle);

            linkedInUrl += encodeURIComponent('Ogeto T et al.');
    
    var offsetTop = /chrome/i.test( navigator.userAgent ) ? 4 : -10; 
    var addthis_config = {
            ui_offset_top: offsetTop,
                                    services_compact : "facebook,twitter,www.linkedin.com,www.mendeley.com,reddit.com",
            services_expanded : "facebook,twitter,www.linkedin.com,www.mendeley.com,reddit.com",
            services_custom : [
                {
                    name: "LinkedIn",
                    url:  linkedInUrl,
                    icon:"/img/icon/at_linkedin.svg"
                },
                {
                    name: "Mendeley",
                    url:  "http://www.mendeley.com/import/?url=https://f1000research.com/articles/9-680/v1/mendeley",
                    icon:"/img/icon/at_mendeley.svg"
                },
                {
                    name: "Reddit",
                    url:  redditUrl,
                    icon:"/img/icon/at_reddit.svg"
                },
            ]
        };


    var addthis_share = {
            url: "https://f1000research.com/articles/9-680",
            templates : {
                twitter : "Malaria vaccines targeting the pre-erythrocytic stage: a scoping.... Ogeto T et al., published by " + 
               "@F1000Research"
       + ", https://f1000research.com/articles/9-680/v1"
            }
        };

    if (typeof(addthis) != "undefined"){
        addthis.addEventListener('addthis.ready', checkCount);
        addthis.addEventListener('addthis.menu.share', checkCount);
    }

        $(".f1r-shares-twitter").attr("href", "https://twitter.com/intent/tweet?text=" + addthis_share.templates.twitter);
    $(".f1r-shares-facebook").attr("href", "https://www.facebook.com/sharer/sharer.php?u=" + addthis_share.url);
    $(".f1r-shares-linkedin").attr("href", addthis_config.services_custom[0].url);
    $(".f1r-shares-reddit").attr("href", addthis_config.services_custom[2].url);
    $(".f1r-shares-mendelay").attr("href", addthis_config.services_custom[1].url);

    function checkCount(){
        setTimeout(function(){
            $(".addthis_button_expanded").each(function(){
                var count = $(this).text();
                if (count !== "" && count != "0")
                    $(this).removeClass("is-hidden");
                else
                    $(this).addClass("is-hidden");
            });
        }, 1000);
    }
</script> <div id=citeReportModal role=dialog aria-labelledby=citeReportModal_title aria-describedby=citeReportModal_description> <div class="c-modal js-modal is-closed c-modal--large js-cite-report-modal "> <aside class="c-modal__content u-black--high o-box u-pb--0 u-black--high "> <div class=c-modal__close> <button type=button class="c-button c-button--icon c-button--medium c-button--full@hover js-modal__close"><i class="c-button--icon__icon material-icons">close</i></button> </div> <h1 id=citeReportModal_title class="c-modal__title t-h3 u-mt--0 u-mb--2 u-weight--md">How to cite this report</h1> <div id=citeReportModal_description class="c-modal__description js-modal__content t-h4 u-mt--0 u-mb--2 u-black--medium"> <div id="" class=js-report-citation-container>{{reportCitation}}</div> <div class="c-modal__extra-message js-modal__extra-message t-h4 u-black--medium"></div></div> <div class="c-modal__actions o-box__actions"> <a href="#" class="c-button c-button--full js-modal__close c-button--secondary">Cancel</a> <a href="#" title="Copy the current citation details to the clipboard." data-clipboard-target="#referee-report-citation" data-test-id=report_copy-citation_button class="c-button c-button--full js-modal__confirm c-button--primary js-clipboard c-mini-tooltip--above">Copy Citation Details</a> </div> </aside> </div> </div> <script src="/js/referee/new/referee_validators.js"></script> <script src="/js/referee/new/referee_helpers.js"></script> <script src="/js/referee/new/referee_checkbox-input.js"></script> <script src="/js/referee/new/referee_inline-editor.js"></script> <script type="text/javascript">
    $(function(){
        var gaCat = "F1000Research";
        if (gaCat === "") {
            gaCat = $("body").hasClass("wellcome-brand") ? "Wellcome Open Research" : "F1000Research";
        }
        GAHelper.track({category: gaCat, action: "Article Page: Malaria vaccines targeting the pre-erythrocytic stage: a scoping review", label: "pageviews"});
        GAHelper.track({category: gaCat, action: "Article Type: Systematic Review", label: "Article Page"});
        $(".f1r-article-desk .collection-image").each(function (idx, el) {
            var whatChannel = $(el).find("a").attr("href"),
                channelName = $.trim($(el).parent().find(".collection-detail a").text()),
                gaRef = "(ID: " + whatChannel.replace("/collections/", "") + ") " + channelName;
            GAHelper.track({category: 'ChannelStats', action: "Article Page: Malaria vaccines targeting the pre-erythrocytic stage: a scoping review", label: gaRef});
        });
    });
</script> <script>
    $(function(){R.ui.buttonDropdowns('.dropdown-for-downloads');});
    $(function(){R.ui.toolbarDropdowns('.toolbar-dropdown-for-downloads');});
</script> <script src="/js/article/track_article.js" type="text/javascript"></script> <script type="text/javascript">
    $.get("/articles/acj/24320/26833")
</script> <script type="text/javascript" src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js"></script> <script type="text/javascript" src="/js/app/messenger.js"></script> <script type="text/javascript" src="/js/article/article_mobiles.js"></script> <script src="/js/vendor/clipboard.min.js"></script> <script src="/js/shared_scripts/modal-dialogue.js"></script> <script src="/js/shared_scripts/clipboard.js"></script> <script src="/js/article/thesaurus-terms-display.js"></script> <script>
    new F1000.Clipboard();
    new F1000.ThesaurusTermsDisplay("articles", "article", "26833");
</script> <script>
    $(document).ready(function() {
        $( "#frame1" ).on('load', function() {
            var mydiv = $(this).contents().find("div");
            var h     = mydiv.height();
            console.log(h)
        });

        
        var tooltipLivingFigure = jQuery(".interactive-living-figure-label .icon-more-info"),
            titleLivingFigure = tooltipLivingFigure.attr("title");
        tooltipLivingFigure.simpletip({
            fixed: true,
            position: ["-115", "30"],
            baseClass: 'small-tooltip',
            content:titleLivingFigure + "<div class='tooltip-arrow'></div>"
        });
        tooltipLivingFigure.removeAttr("title");

        $("body").on("click", ".cite-living-figure", function(e) {
            e.preventDefault();
            var ref = $(this).attr("data-ref");
            $(this).closest(".living-figure-list-container").find("#" + ref).fadeIn(200);
        });
        $("body").on("click", ".close-cite-living-figure", function(e) {
            e.preventDefault();
            $(this).closest(".popup-window-wrapper").fadeOut(200);
        });

                $(document).on("mouseup", function(e) {
            var metricsContainer = $(".article-metrics-popover-wrapper");
            if (!metricsContainer.is(e.target) && metricsContainer.has(e.target).length === 0) {
                $(".article-metrics-close-button").click();
            }
        });

        var articleId = $('#articleId').val();

        if($("#main-article-count-box").attachArticleMetrics) {
            $("#main-article-count-box").attachArticleMetrics(articleId, {
                articleMetricsView: true
            });
        }
    });

    var figshareWidget = $(".new_figshare_widget");
    if (figshareWidget.length > 0) {
        window.figshare.load("f1000", function(Widget) {
            // Select a tag/tags defined in your page. In this tag we will place the widget.
            _.map(figshareWidget, function(el){
                var widget = new Widget({
                    articleId: $(el).attr("figshare_articleId")
                    //height:300 // this is the height of the viewer part. [Default: 550]
                });
                widget.initialize(); // initialize the widget
                widget.mount(el); // mount it in a tag that's on your page
                // this will save the widget on the global scope for later use from
                // your JS scripts. This line is optional.
                //window.widget = widget;
            });
        });
    }
</script>

<script>
    $(document).ready(function () {

        
        var reportIds = {
                           "66593": 0,
                           "66592": 0,
                           "66595": 0,
                           "69801": 0,
                           "66603": 0,
                           "66602": 0,
                           "69399": 0,
                           "69241": 0,
                           "69401": 0,
                           "69400": 0,
                           "69403": 0,
                           "69402": 0,
                           "69242": 0,
                    };

        $(".referee-response-container,.js-referee-report").each(function(index, el) {
            var reportId = $(el).attr("data-reportid"),
                reportCount = reportIds[reportId] || 0;
            $(el).find(".comments-count-container,.js-referee-report-views").html(reportCount);
        });

        var uuidInput = $("#article_uuid"),
            oldUUId = uuidInput.val(),
            newUUId = "09b6d0b7-472c-4f8a-b3a5-455a2a2a5af4";
        uuidInput.val(newUUId);

        $("a[href*='article_uuid=']").each(function(index, el) {
            var newHref = $(el).attr("href").replace(oldUUId, newUUId);
            $(el).attr("href", newHref);
        });

    });
</script>              </div>
        </div>

        
            
            <div class="o-page__footer sticky-email-wrapper">
                
                

                


<footer class="c-footer t-inverted">

    <div class="o-wrapper">
        <div class="o-layout">


                        
            <div class="o-layout__item u-mb--3">
                <div class="c-branding c-branding--research">
                    <img src="/img/research/F1000Research_white.svg" alt="F1000Research">
                </div>
            </div>


                        
            <div class="o-layout__item u-1/3@md u-mb--3">

                <span class="c-hr c-hr--thick c-hr--low u-mb--2"></span>

                <p class="t-h3 u-mt--0 u-mb--0">An innovative open access publishing platform offering rapid publication and open peer review, whilst supporting data deposition and sharing.</p>

            </div>


                        
            <div class="o-layout__item u-2/3@md">

                <span class="c-hr c-hr--thick c-hr--low u-mb--2"></span>

                <div class="o-layout">
                    <nav class="c-footer__nav">

                            <div class="o-layout__item u-3/5@sm u-mb--3">


                                <div class="o-columns o-columns--2">

                                                                            <a href="/browse/articles" class="t-body c-footer__nav-item "      >Browse</a>
                                                                            <a href="/gateways" class="t-body c-footer__nav-item "      >Gateways</a>
                                                                            <a href="/collections" class="t-body c-footer__nav-item "      >Collections</a>
                                                                            <a href="/about" class="t-body c-footer__nav-item "      >How it Works</a>
                                                                            <a href="https://blog.f1000.com/blogs/f1000research/" class="t-body c-footer__nav-item "      >Blog</a>
                                                                            <a href="/contact" class="t-body c-footer__nav-item "      >Contact</a>
                                                                            <a href="/developers" class="t-body c-footer__nav-item u-hide u-show@navbar"      >For Developers</a>
                                                                            <a href="/published/rss" class="t-body c-footer__nav-item "   title="RSS feed of published articles"     >RSS</a>
                                    
                                </div>

                            </div>

                            <div class="o-layout__item u-2/5@sm u-center u-right@sm u-mb--3">

                                <div class="u-hide u-show@lg">
                                    <div class="_mdl-layout">
                                        <a class="mdl-button mdl-js-button mdl-button--inverted mdl-button--no-shadow mdl-js-ripple-effect mdl-button--outline" href="/for-authors/publish-your-research"   data-test-id="footer_submit_research"  >Submit Your Research</a>
                                    </div>
                                </div>

                            </div>

                    </nav>
                </div>

            </div>

            <div class="o-layout__item u-mb--2">
                <div class="c-footer__share">
                        <div class="c-footer__share">
        <span class="c-footer__share-icon" title="Open Access">
            <span class="f1r-icon icon-100_open_access license-icon"></span>
        </span>

        <a class="c-footer__share-icon" href="//creativecommons.org/licenses" target="_blank" title="Creative Commons License CC-BY">
            <span class="f1r-icon icon-116_cc license-icon license-icon-cc"></span>
            <span class="f1r-icon icon-117_ccby license-icon license-icon-cc"></span>
        </a>

        <a class="c-footer__share-icon" href="//creativecommons.org/about/cc0" target="_blank" title="Creative Commons License CC0">
            <span class="f1r-icon icon-118_cco license-icon"></span>
        </a>

    </div>
                </div>
            </div>


                        
            <div class="o-layout__item u-1/3@md u-mb--3">

                <span class="c-hr c-hr--low u-mb--3"></span>

                <p class="c-footer__social u-mt--0 u-mb--0 u-white--low-med">Follow us
                    <a href="https://www.facebook.com/F1000" target="_blank" class="c-footer__social-icon f1r-icon icon-55_footer_facebook"></a>
                    <a href="https://twitter.com/#!/F1000Research" target="_blank" class="c-footer__social-icon f1r-icon icon-56_footer_twitter"></a>
                    <a href="http://www.youtube.com/user/F1000research" target="_blank" class="c-footer__social-icon f1r-icon icon-57_footer_youtube"></a></p>

            </div>


                        
            <div class="o-layout__item u-2/3@md u-right@md">

                <span class="c-hr c-hr--low u-mb--3"></span>

                <p class="t-caption u-white--low-med">&copy; 2012-2020 F1000 Research Ltd. ISSN 2046-1402 | <a href="/about/legal" class="copyrightLegal">Legal</a> | Partner of <a target="_blank" href="http://www.who.int/hinari/en/">HINARI</a>  &bull; <a target="_blank" href="http://crossref.org/">CrossRef</a> &bull; <a target="_blank" href="http://about.orcid.org/">ORCID</a> &bull; <a target="_blank" href="http://www.fairsharing.org">FAIRSharing</a></p>

            </div>
        </div>
    </div>

</footer>            </div>
        
    </div>

            <div class="js-cookie-spacer"></div>
        <div class="cookie-warning">
            <div class="instruction">The F1000Research website uses cookies. By continuing to browse the site, you are agreeing to our use of cookies. <a class="js-scroll-to" href="/about/legal/privacypolicy#use-of-cookies" data-scroll-target="#use-of-cookies">Find out more &raquo;</a></div>
            <div class="close-button"></div>
        </div>
    
    <script>
                    R.templateTests.simpleTemplate = R.template('<p class="$variable.one">$text</p><p class="${variable.two}">$text</p><p class="$!variable.three">$text</p><p class="$!{variable.four}">$text</p><p class="${selector}.five">$text</p>');
            R.templateTests.runTests();
        
        var F1000platform = new F1000.Platform({
            name: "f1000research",
            displayName: "F1000Research",
            hostName: "f1000research.com",
            id: "1",
            editorialEmail: "research@f1000.com",
            infoEmail: "info@f1000.com",
            usePmcStats: true
        });

                    $(function(){R.ui.dropdowns('.dropdown-for-authors, .dropdown-for-about, .dropdown-for-myresearch');});
            // $(function(){R.ui.dropdowns('.dropdown-for-referees');});

            $(document).ready(function () {
                if ($(".cookie-warning").is(":visible")) {
                    $(".sticky").css("margin-bottom", "35px");
                    $(".devices").addClass("devices-and-cookie-warning");
                }
                $(".cookie-warning .close-button").click(function (e) {
                    $(".devices").removeClass("devices-and-cookie-warning");
                    $(".sticky").css("margin-bottom", "0");
                });

                $("#tweeter-feed .tweet-message").each(function (i, message) {
                    var self = $(message);
                    self.html(linkify(self.html()));
                });

                $(".partner").on("mouseenter mouseleave", function() {
                    $(this).find(".gray-scale, .colour").toggleClass("is-hidden");
                });
            });
        
    </script>

            
<div class="sign-in-popup">
	<!-- <a href="#" class="sign-in shadow">Sign in <span class="sign-in-image-active"></span></a> -->
	<a href="#" class="sign-in ${locale}">Sign In <span class="arrow-closed sign-in-arrow-padding arrow-opened"></span></a>
	<div class="sign-in-form">

            <form action="https://f1000research.com/j_spring_oauth_security_check" id="googleOAuth" method="post"  target="_top" >
                                    <input class="target-field" type="hidden" name="target" value="/articles/9-680.html"/>
                            <input id="google-remember-me" name="_spring_security_oauth_remember_me" type="hidden" value="true"/>
        <input id="system-google" name="system" type="hidden" value="GOOGLE"/>
    </form>
            <form action="https://f1000research.com/j_spring_oauth_security_check" id="facebookOAuth" method="post"  target="_top" >
                                    <input class="target-field" type="hidden" name="target" value="/articles/9-680.html"/>
                            <input id="facebook-remember-me" name="_spring_security_oauth_remember_me" type="hidden" value="true"/>
        <input id="system-fb" name="system" type="hidden" value="FACEBOOK"/>
    </form>
            <form action="https://f1000research.com/j_spring_oauth_security_check" id="orcidOAuth" method="post"  target="_top" >
                                    <input class="target-field" type="hidden" name="target" value="/articles/9-680.html"/>
                            <input id="orcid-remember-me" name="_spring_security_oauth_remember_me" type="hidden" value="true"/>
        <input id="system-orcid" name="system" type="hidden" value="ORCID"/>
    </form>
		<form id="sign-in-form" class="login-container" action="https://f1000research.com/login" method="post" name="f">
           <div id="sign-in-form-gfb-popup"></div>

                                                            <input class="target-field" type="hidden" name="target" value="/articles/9-680.html"/>
                            			<input type="text" name="username" id="signin-email-box" class="sign-in-input" placeholder="Email address" autocomplete="email">
			<input type="password" name="password" id="signin-password-box" class="sign-in-input" placeholder="Password" autocomplete="current-password">
			<div class="sign-in-remember">
                <div class="checkbox-wrapper">
    				<input type="checkbox" id="remember-me" name="remember_me" class="checkbox is-hidden">
                </div>
                <span class="checkbox-label">Remember me</span>
			</div>
			<a href="#" class="sign-in-link" id="forgot-password-link">Forgotten your password?</a>
			<div class="sign-in-button-container margin-top margin-left-20 margin-bottom">
				<button type="submit" id="sign-in-button" class="sign-in-buttons general-white-orange-button">Sign In</button>
				<button type="button" id="sign-in-cancel" class="sign-in-buttons sign-in-cancel-button margin-left">Cancel</button>
				<div class="clearfix"></div>
			</div>
			<div class="sign-in-error">Email or password not correct. Please try again</div>
			<div class="sign-in-loading">Please wait...</div>
		</form>
		<div class="forgot-password-container">
			
<script type="text/javascript">
	$(function(){
		// Note: All the setup needs to run against a name attribute and *not* the id due the clonish
		// nature of facebox...
		$("a[id=googleSignInButton]").click(function(event){
            event.preventDefault();
            $("input[id=oAuthSystem]").val("GOOGLE");
            $("form[id=oAuthForm]").submit();
        });
        $("a[id=facebookSignInButton]").click(function(event){
            event.preventDefault();
            $("input[id=oAuthSystem]").val("FACEBOOK");
            $("form[id=oAuthForm]").submit();
        });
        $("a[id=orcidSignInButton]").click(function(event){
            event.preventDefault();
            $("input[id=oAuthSystem]").val("ORCID");
            $("form[id=oAuthForm]").submit();
        });
	});
</script>

<span class="text first">
	If you've forgotten your password, please enter your email address below and we'll send you instructions on how to reset your password.
    <p>The email address should be the one you originally registered with F1000.</p>
</span>
<input name="email" class="sign-in-input" id="email-forgot-password" type="text" placeholder="Email address">
<div class="forgot-password-email-error">
	Email address not valid, please try again
</div>
<div class="forgot-password-google-email-error">
    <p>You registered with F1000 via Google, so we cannot reset your password.</p>
	<p>To sign in, please click <a href="#" id="googleSignInButton">here</a>.</p>
    <p>If you still need help with your Google account password, please click <a href="https://www.google.com/accounts/recovery">here</a>.</p>
</div>
<div class="forgot-password-facebook-email-error">
    <p>You registered with F1000 via Facebook, so we cannot reset your password.</p>
    <p>To sign in, please click <a href="#" id="facebookSignInButton">here</a>.</p>
	<p>If you still need help with your Facebook account password, please click <a href="https://www.facebook.com/recover/initiate">here</a>.</p>
</div>
<div class="clearfix"></div>
<div class="forgot-password-captcha-error">
	Code not correct, please try again
</div>
<div class="clearfix"></div>
<div class="sign-in-button-container margin-left-20 margin-bottom">
	<button type="button" id="sign-in-reset-password" class="sign-in-buttons general-white-orange-button">Reset password</button>
	<button type="button" id="forgot-password-cancel" class="sign-in-buttons sign-in-cancel-button margin-left">Cancel</button>
	<div class="clearfix"></div>
</div>
<span class="text last">
	<a href="mailto:">Email us</a> for further assistance.
</span>
<form action="https://f1000research.com/j_spring_oauth_security_check" id="oAuthForm" method="post" target="_top">
                        <input class="target-field" type="hidden" name="target" value="/articles/9-680.html"/>
                <input id="oAuthSystem" name="system" type="hidden"/>
</form>
			<div class="forgot-password-server-error">Server error, please try again.</div>
			<div class="sign-in-success">
                <p>We have sent an email to <span id="email-value"></span>, please follow the instructions to reset your password.</p>
                <p>If you don't receive this email, please check your spam filters and/or contact .</p>
            </div>
			<div class="sign-in-loading">Please wait...</div>
		</div>

		<div class="sign-in-form-register-section">
			<div class="sign-in-button-container margin-left-20 margin-bottom">
				<a href="/register" title="Register"><button type="button" id="sign-in-register-button" class="sign-in-buttons general-white-orange-button">Register</button></a>
				<div class="clearfix"></div>
			</div>
		</div>

	</div>
</div>

<script type="text/javascript">
$(document).ready(function () {

    signIn.createSignInAsRow($("#sign-in-form-gfb-popup"));

    $(".target-field").each(function () {
        var uris = $(this).val().split("/");
        if (uris.pop() === "login") {
        	$(this).val(uris.toString().replace(",","/"));
        }
    });
});
</script>
        <div id="templateOverlay" class="is-hidden" hidden="hidden">
  <div class="o-overlay js-overlay is-hidden" hidden="hidden"></div>
</div>

<div id="templateExternalMessages" class="is-hidden" hidden="hidden">
  <div class="o-modal o-modal--auto@md js-external-messages is-hidden" hidden="hidden">
    <div class="o-modal__body">
      <section class="c-console">
        <div class="_mdl-layout c-console__bdy js-external-messages-body"></div>
        <footer class="_mdl-layout c-console__ftr o-flex o-flex--reverse js-external-messages-footer">
          <button type="button" class="mdl-button mdl-js-button mdl-button--raised mdl-button--colored c-console__btn js-external-messages-close" data-action="maintenance-close">I Understand</button>
        </footer>
      </section>
    </div>
  </div>
</div>

<script src="https://cdnjs.cloudflare.com/ajax/libs/moment.js/2.22.1/moment.min.js"></script>

<script src="/js/namespace.js"></script>
<script src="/js/constants.js"></script>
<script src="/js/utilities.js"></script>

<script>
                  F1000.ExtenalMaintenanceItems = [
    {
      start: '2018-12-10T14:21:00Z',
      end: '2018-12-13T16:00:00Z',
      msg: 'This site will be down for a short time on XX December. It is advisable not to start any submissions on that day or you may lose your work unless you save regularly.',
      cookieName: 'outage23122018',
      editor: false,
    }
  ];
</script>

<script src="/js/shared_scripts/cookie-helper.js"></script>
<script src="/js/shared_scripts/mdl-helper.js"></script>

<script src="/js/app/external-maintenance.js"></script>

                <script type="text/javascript">
            (function(i,s,o,g,r,a,m){i['GoogleAnalyticsObject']=r;i[r]=i[r]||function(){
            (i[r].q=i[r].q||[]).push(arguments)},i[r].l=1*new Date();a=s.createElement(o),
            m=s.getElementsByTagName(o)[0];a.async=1;a.src=g;m.parentNode.insertBefore(a,m)
            })(window,document,'script','//www.google-analytics.com/analytics.js','ga');

            ga('create', 'UA-5646075-11', 'auto');
            ga('require', 'displayfeatures');
            ga('send', 'pageview');
        </script>
        
                <script type="text/javascript" src="/js/app/research.analytics.js"></script>

        <!-- Start of HubSpot Embed Code -->
        <script type="text/javascript" id="hs-script-loader" async defer src="//js.hs-scripts.com/4475190.js"></script>
        <!-- End of HubSpot Embed Code -->
    
            <script src="https://my.hellobar.com/4e0495c6f18cbd68731a1dc1978195a144e767ba.js" type="text/javascript" charset="utf-8" async="async"></script>
    </body>

</html>